

ABALOPARATIDE

Products Affected

- TYMLOS

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 MONTHS |
| Other Criteria | OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ABATACEPT IV

Products Affected

- ORENCIA INTRAVENOUS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. |
| Coverage Duration | RA, PJIA, PSA: INITIAL: 6 MOS, RENEWAL: 12 MOS. ACUTE GRAFT VERSUS HOST DISEASE (AGVHD): 1 MO. |
| Other Criteria | INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA, PJIA, PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

ABATACEPT SQ

Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PJIA, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

ABEMACICLIB

Products Affected

- VERZENIO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ABIRATERONE

Products Affected

- *abiraterone acetate*
- *abirtega*

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ABIRATERONE SUBMICRONIZED

Products Affected

- ABIRATERONE ACETATE MICRONIZED
- YONSA

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ACALABRUTINIB

Products Affected

- CALQUENCE

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

ACORAMIDIS

Products Affected

- ATTRUBY

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | CARDIOMYOPATHY OF WILD TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM): INITIAL: 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS I, II, OR III HEART FAILURE, AND 2) DIAGNOSIS CONFIRMED BY (A) BONE SCAN (SCINTIGRAPHY) STRONGLY POSITIVE FOR MYOCARDIAL UPTAKE OF TC-99M-PYP, OR (B) BIOPSY OF TISSUE OF AFFECTED ORGAN(S) (CARDIAC AND POSSIBLY NON-CARDIAC SITES) TO CONFIRM AMYLOID PRESENCE AND CHEMICAL TYPING TO CONFIRM PRESENCE OF TRANSTHYRETIN (TTR) PROTEIN. |
| Age Restrictions | |
| Prescriber Restrictions | ATTR-CM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ATTR SPECIALIST, OR MEDICAL GENETICIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | ATTR-CM: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER ATTR-CM TTR STABILIZERS (E.G., TAFAMIDIS). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ADAGRASIB

Products Affected

- KRAZATI

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

ADALIMUMAB

Products Affected

- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PED<40KG CROHNS STARTER
- HUMIRA-PED>=40KG CROHNS START
- HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST. |
| Coverage Duration | INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS. |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Other Criteria | <p>INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ADALIMUMAB-AATY

Products Affected

- *adalimumab-aaty (1 pen) auto-injector kit 40 mg/0.4ml subcutaneous*
- *adalimumab-aaty (1 pen) subcutaneous auto-injector kit 80 mg/0.8ml*
- *adalimumab-aaty (2 pen)*
- *adalimumab-aaty (2 syringe)*
- *adalimumab-aaty cd/uc/hs start*
- YUFLYMA (1 PEN)
- YUFLYMA (2 SYRINGE)
- YUFLYMA-CD/UC/HS STARTER

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST. |
| Coverage Duration | INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | <p>MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ADALIMUMAB-ADBIM

Products Affected

- CYLTEZO (2 PEN)
- CYLTEZO (2 SYRINGE)
- CYLTEZO-CD/UC/HS STARTER
- CYLTEZO-PSORIASIS/UV STARTER

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RA, PJA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST. |
| Coverage Duration | INITIAL: RA, PSO, PJA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| | TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ADALIMUMAB-BWWD

Products Affected

- HADLIMA
- HADLIMA PUSH TOUCH

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST. |
| Coverage Duration | INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

AFATINIB

Products Affected

- GILOTRIF

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ALECTINIB

Products Affected

- ALECENSA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

ALPELISIB-PIQRAY

Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

AMIKACIN LIPOSOMAL INH

Products Affected

- ARIKAYCE

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE: RENEWAL: 1) NO POSITIVE MAC SPUTUM CULTURE AFTER CONSECUTIVE NEGATIVE CULTURES, AND 2) IMPROVEMENT IN SYMPTOMS. ADDITIONALLY, FOR FIRST RENEWAL, APPROVAL REQUIRES AT LEAST ONE NEGATIVE SPUTUM CULTURE FOR MAC BY SIX MONTHS OF ARIKAYCE TREATMENT. FOR SECOND AND SUBSEQUENT RENEWALS, APPROVAL REQUIRES AT LEAST THREE NEGATIVE SPUTUM CULTURES FOR MAC BY 12 MONTHS OF ARIKAYCE TREATMENT. |
| Age Restrictions | |
| Prescriber Restrictions | MAC LUNG DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR INFECTIOUS DISEASE SPECIALIST. |
| Coverage Duration | INITIAL/RENEWAL: 6 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

AMIVANTAMAB-HYALURONIDASE-LPUJ

Products Affected

- RYBREVANT FASPRO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

AMIVANTAMAB-VMJW

Products Affected

- RYBREVANT

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ANAKINRA

Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS. |
| Required Medical Information | INITIAL: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES. DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. |
| Coverage Duration | RA: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. CAPS, DIRA: LIFETIME. |
| Other Criteria | INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| | ORENCIA. RENEWAL: RA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

APALUTAMIDE

Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

APOMORPHINE - ONAPGO

Products Affected

- ONAPGO

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | PD: RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

APOMORPHINE - SL

Products Affected

- KYNMOBI

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OF AGE OR OLDER. |
| Prescriber Restrictions | PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | PD: RENEWAL: IMPROVEMENT WITH MOTOR FLUCTUATIONS DURING OFF EPISODES WITH THE USE OF THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

APREMILAST

Products Affected

- OTEZLA
- OTEZLA XR
- OTEZLA/OTEZLA XR INITIATION PK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: MILD PLAQUE PSORIASIS (PSO): 1) PSORIASIS COVERING LESS THAN 3 PERCENT OF BODY SURFACE AREA (BSA), 2) STATIC PHYSICIAN GLOBAL ASSESSMENT (SPGA) SCORE OF 2, OR 3) PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORE OF 2 TO 9. MODERATE TO SEVERE PSO: PSORIASIS COVERING 3 PERCENT OR MORE OF BSA, OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. BEHCETS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: MILD PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL SYSTEMIC THERAPY (E.G., METHOTREXATE, ACITRETIN, CYCLOSPORINE) OR ONE CONVENTIONAL TOPICAL THERAPY (E.G., TOPICAL CORTICOSTEROIDS). MODERATE TO SEVERE PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. BEHCETS |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | DISEASE: 1) HAS ORAL ULCERS OR A HISTORY OF RECURRENT ORAL ULCERS BASED ON CLINICAL SYMPTOMS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OR MORE CONSERVATIVE TREATMENTS (E.G., COLCHICINE, TOPICAL CORTICOSTEROID, ORAL CORTICOSTEROID). INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ARIMOCLOMOL

Products Affected

- MIPLYFFA

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | NIEMANN-PICK DISEASE TYPE C (NPC): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH NEUROLOGIST OR GENETICIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | NPC: RENEWAL: IMPROVEMENT OR SLOWING OF DISEASE PROGRESSION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ASCIMINIB

Products Affected

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | PREVIOUSLY TREATED OR T315I MUTATION PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND SCEMBLIX IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ASFOTASE ALFA

Products Affected

- STRENSIQ

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | HYPOPHOSPHATASIA (HPP): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, GENETICIST, OR METABOLIC SPECIALIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PERINATAL/INFANTILE-ONSET HPP: 1) 6 MONTHS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC CHEST DEFORMITY, (II) CRANIOSYNOSTOSIS, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OF VITAMIN B6 DEPENDENT SEIZURES, (V) NEPHROCALCINOSIS OR HISTORY OF ELEVATED SERUM CALCIUM, (VI) HISTORY OR PRESENCE OF NON-TRAUMATIC POSTNATAL FRACTURE AND DELAYED FRACTURE HEALING. JUVENILE-ONSET HPP: 1) 18 YEARS OF |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| | <p>AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TNSALP ALPL GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALP LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PLP LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PEA LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC DEFORMITIES, (II) PREMATURE LOSS OF PRIMARY TEETH PRIOR TO 5 YEARS OF AGE, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OR PRESENCE OF NON-TRAUMATIC FRACTURES OR DELAYED FRACTURE HEALING. ALL INDICATIONS: 1) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE, 2) CALCIUM OR PHOSPHATE LEVELS ARE NOT BELOW THE NORMAL RANGE, 3) NOT HAVE A TREATABLE FORM OF RICKETS. RENEWAL: ALL INDICATIONS: 1) IMPROVEMENT IN THE SKELETAL CHARACTERISTICS OF HPP, AND 2) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ATOGEPANT

Products Affected

- QULIPTA

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

AVACOPAN

Products Affected

- TAVNEOS

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS: INITIAL: ANCA SEROPOSITIVE (ANTI-PR3 OR ANTI-MPO). |
| Age Restrictions | |
| Prescriber Restrictions | ANCA-ASSOCIATED VASCULITIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 6 MONTHS. |
| Other Criteria | ANCA-ASSOCIATED VASCULITIS: RENEWAL: CONTINUES TO BENEFIT FROM THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

AVAPRITINIB

Products Affected

- AYVAKIT

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

AVUTOMETINIB-DEFACTINIB

Products Affected

- AVMAPKI FAKZYNJA CO-PACK

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

AXATILIMAB-CSFR

Products Affected

- NIKTIMVO

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | CHRONIC GRAFT VS HOST DISEASE (CGVHD): 1) FAILURE OF AT LEAST TWO LINES OF SYSTEMIC THERAPY, ONE OF WHICH MUST BE A TRIAL OF OR CONTRAINDICATION TO JAKAFI, AND 2) NO CONCURRENT USE WITH JAKAFI, REZUROCK, OR IMBRUVICA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

AXITINIB

Products Affected

- INLYTA ORAL TABLET 1 MG, 5 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

AZACITIDINE

Products Affected

- ONUREG

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

AZTREONAM INHALED

Products Affected

- CAYSTON

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | 7 YEARS OF AGE OR OLDER |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

BEDAQUILINE

Products Affected

- SIRTURO

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 WEEKS |
| Other Criteria | N/A |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

BELIMUMAB

Products Affected

- BENLYSTA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. LUPUS NEPHRITIS (LN): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL: SLE: CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. RENEWAL: SLE: PATIENT HAD CLINICAL IMPROVEMENT. LN: IMPROVEMENT IN RENAL RESPONSE FROM BASELINE LABORATORY VALUES (I.E., EGFR OR PROTEINURIA) AND/OR CLINICAL PARAMETERS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

BELUMOSUDIL

Products Affected

- REZUROCK

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | CHRONIC GRAFT VS HOST DISEASE (CGVHD): 1) FAILURE OF AT LEAST TWO LINES OF SYSTEMIC THERAPY, ONE OF WHICH MUST BE A TRIAL OF OR CONTRAINDICATION TO JAKAFI, AND 2) NO CONCURRENT USE WITH JAKAFI, NIKTIMVO, OR IMBRUVICA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

BELZUTIFAN

Products Affected

- WELIREG

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

BENDAMUSTINE

Products Affected

- BENDAMUSTINE HCL
INTRAVENOUS SOLUTION
- *bendamustine hcl intravenous solution reconstituted*
- BENDEKA
- VIVIMUSTA

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

BENRALIZUMAB

Products Affected

- FASENRA
- FASENRA PEN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE, OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ASTHMA: 1) CONTINUED USE OF ICS AND ONE |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| | OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

BETAINE

Products Affected

- *betaine*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

BEVACIZUMAB-BVZR

Products Affected

- ZIRABEV

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

BEXAROTENE

Products Affected

- *bexarotene*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

BINIMETINIB

Products Affected

- MEKTOVI

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

BORTEZOMIB

Products Affected

- BORTEZOMIB INJECTION SOLUTION RECONSTITUTED 1 MG, 2.5 MG
- *bortezomib injection solution reconstituted 3.5 mg*
- BORUZU

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

BOSENTAN

Products Affected

- *bosentan oral tablet*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | PAH: INITIAL: 1) DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASE IN BILIRUBIN BY 2 OR MORE TIMES ULN, AND 2) NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE. RENEWAL: NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

BOSUTINIB

Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND BOSULIF IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

BRIGATINIB

Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

C1 ESTERASE INHIBITOR-HAEGARDA

Products Affected

- HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | HEREDITARY ANGIOEDEMA (HAE): INITIAL: 1) TYPE III HAE, OR 2) TYPE I OR II HAE CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTS: C1-INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q. |
| Age Restrictions | |
| Prescriber Restrictions | HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, IMMUNOLOGIST, ALLERGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | HAE: INITIAL/RENEWAL: NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

CABOZANTINIB CAPSULE

Products Affected

- COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

CABOZANTINIB TABLET

Products Affected

- CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

CANNABIDIOL

Products Affected

- EPIDIOLEX

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: DRAVET SYNDROME (DS), LENNOX-GASTAUT SYNDROME (LGS), TUBEROUS SCLEROSIS COMPLEX (TSC): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

CAPIVASERTIB

Products Affected

- TRUQAP ORAL TABLET 200 MG
- TRUQAP ORAL TABLET THERAPY PACK 160 MG

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

CAPMATINIB

Products Affected

- TABRECTA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

CARGLUMIC ACID

Products Affected

- carglumic acid oral tablet soluble*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: ACUTE OR CHRONIC HYPERAMMONEMIA (HA) DUE TO N ACETYLGLUTAMATE SYNTHASE (NAGS) DEFICIENCY: NAGS GENE MUTATION IS CONFIRMED BY BIOCHEMICAL OR GENETIC TESTING. ACUTE HA DUE TO PROPIONIC ACIDEMIA (PA): 1) CONFIRMED BY ELEVATED METHYLCITRIC ACID AND NORMAL METHYLMALONIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE PCCA OR PCCB GENE. ACUTE HA DUE TO METHYLMALONIC ACIDEMIA (MMA): 1) CONFIRMED BY ELEVATED METHYLMALONIC ACID, METHYLCITRIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE MMUT, MMA, MMAB OR MMADHC GENES. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | ACUTE HA DUE TO NAGS/PA/MMA: 7 DAYS. CHRONIC HA DUE TO NAGS: INITIAL: 6 MOS, RENEWAL: 12 MOS. |
| Other Criteria | RENEWAL: CHRONIC HA DUE TO NAGS: PATIENT HAS SHOWN CLINICAL IMPROVEMENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

CERITINIB

Products Affected

- ZYKADIA ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

CERTOLIZUMAB PEGOL

Products Affected

- CIMZIA (1 SYRINGE)
- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG
- CIMZIA-STARTER

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI). |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, XELJANZ, |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | <p>RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA. AS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ. CD: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, RINVOQ, SKYRIZI, TREMFYA. PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, SKYRIZI, TREMFYA, OTEZLA. NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL FOR RA, PSA, PSO, AS, CD, PJIA: TRIAL OF OR CONTRAINDICATION TO THE STEP AGENTS IS NOT REQUIRED IF THE PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL FOR RA, PSA, AS, PSO, NR-AXSPA, PJIA: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

CETUXIMAB

Products Affected

- ERBITUX

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

CLADRIBINE

Products Affected

- MAVENCLAD (10 TABS)
- MAVENCLAD (4 TABS)
- MAVENCLAD (5 TABS)
- MAVENCLAD (6 TABS)
- MAVENCLAD (7 TABS)
- MAVENCLAD (8 TABS)
- MAVENCLAD (9 TABS)

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 48 WEEKS. |
| Other Criteria | RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): HAS NOT RECEIVED A TOTAL OF TWO YEARS OF MAVENCLAD TREATMENT (I.E., TWO YEARLY TREATMENT COURSES OF TWO CYCLES IN EACH). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

CLOBAZAM-SYMPAZAN

Products Affected

- SYMPAZAN

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: LENNOX-GASTAUT SYNDROME (LGS): THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | LGS: INITIAL: CONTRAINDICATION TO OR UNABLE TO SWALLOW CLOBAZAM TABLETS OR SUSPENSION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

COBIMETINIB

Products Affected

- COTELLIC

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

CORTICOTROPIN

Products Affected

- CORTROPHIN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | INITIAL: NOT APPROVED FOR DIAGNOSTIC PURPOSES. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MULTIPLE SCLEROSIS (MS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, ALLERGIST/IMMUNOLOGIST, OPHTHALMOLOGIST, PULMONOLOGIST OR NEPHROLOGIST. |
| Coverage Duration | INFANTILE SPASMS AND MS: 28 DAYS. ALL OTHER FDA APPROVED INDICATIONS: INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS: TRIAL OF OR CONTRAINDICATION TO INTRAVENOUS (IV) CORTICOSTEROIDS. RENEWAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MS: DEMONSTRATED CLINICAL BENEFIT WHILE ON THERAPY AS INDICATED BY SYMPTOM RESOLUTION AND/OR NORMALIZATION OF LABORATORY TESTS. PART B BEFORE PART D STEP THERAPY, APPLIES ONLY TO BENEFICIARIES IN AN MA-PD PLAN. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

CRIZOTINIB CAPSULE

Products Affected

- XALKORI ORAL CAPSULE

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

CRIZOTINIB PELLETS

Products Affected

- XALKORI ORAL CAPSULE SPRINKLE
150 MG, 20 MG, 50 MG

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | NON-SMALL CELL LUNG CANCER (NSCLC), ANAPLASTIC LARGE CELL LYMPHOMA (ALCL), INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT): UNABLE TO SWALLOW CAPSULES. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

DABRAFENIB CAPSULES

Products Affected

- TAFINLAR ORAL CAPSULE

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

DABRAFENIB SUSPENSION

Products Affected

- TAFINLAR ORAL TABLET SOLUBLE

| PA Criteria | Criteria Details |
|-------------------------------|--------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | UNABLE TO SWALLOW TAFINLAR CAPSULES. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

DACOMITINIB

Products Affected

- VIZIMPRO

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

DALFAMPRIDINE

Products Affected

- *dalfampridine er*

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | MULTIPLE SCLEROSIS (MS): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | MS: INITIAL: HAS SYMPTOMS OF A WALKING DISABILITY (E.G., MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS, UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA). RENEWAL: IMPROVEMENT IN WALKING ABILITY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

DAROLUTAMIDE

Products Affected

- NUBEQA

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

DASATINIB

Products Affected

- *dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND DASATINIB IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

DATOPOTAMAB DERUXTECAN-DLNK

Products Affected

- DATROWAY

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

DECITABINE/CEDAZURIDINE

Products Affected

- INQOVI

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

DEFERASIROX

Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000 MCG/L. CHRONIC IRON OVERLOAD IN NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT): 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS), AND 2) LIVER IRON CONCENTRATION (LIC) OF 5 MG FE/G OF LIVER DRY WEIGHT OR GREATER. RENEWAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 500 MCG/L. NTDT: 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS) OR 2) LIC OF 3 MG FE/G OF LIVER DRY WEIGHT OR GREATER. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS OR NTDT: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS OR NTDT: DEFERASIROX SPRINKLE PACKETS: TRIAL OF OR CONTRAINDICATION TO GENERIC DEFERASIROX ORAL TABLET OR TABLET FOR ORAL SUSPENSION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

DENOSUMAB-BMWO - OSENVELT

Products Affected

- OSENVELT

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

DEUTETRABENAZINE

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR PATIENT TITRATION

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | HUNTINGTON DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. TARDIVE DYSKINESIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | TARDIVE DYSKINESIA: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

DEXTROMETHORPHAN QUINIDINE

Products Affected

- NUEDEXTA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

DICLOFENAC TOPICAL SOLUTION

Products Affected

- *diclofenac sodium external solution 2 %*

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 MONTHS |
| Other Criteria | OSTEOARTHRITIS OF THE KNEE: TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF DICLOFENAC SODIUM 1.5% TOPICAL DROPS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

DICLOFENAC-FLECTOR

Products Affected

- *diclofenac epolamine external*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

DIMETHYL FUMARATE

Products Affected

- *dimethyl fumarate oral capsule delayed release 120 mg, 240 mg*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

DIROXIMEL FUMARATE

Products Affected

- VUMERITY

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

DORDA VIPRONE

Products Affected

- MODEYSO

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

DOSTARLIMAB-GXLY

Products Affected

- JEMPERLI

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

DRONABINOL CAPSULE

Products Affected

- *dronabinol*

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 MONTHS |
| Other Criteria | NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY: TRIAL OF OR CONTRAINDICATION TO ONE ANTIEMETIC THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

DROXIDOPA

Products Affected

- *droxidopa*

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH): INITIAL: 1) BASELINE BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE POSITION. 2) A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION. |
| Age Restrictions | |
| Prescriber Restrictions | NOH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST. |
| Coverage Duration | INITIAL: 3 MONTHS RENEWAL: 12 MONTHS |
| Other Criteria | NOH: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

DUPILUMAB

Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: EOSINOPHILIC ASTHMA: BLOOD EOSINOPHIL LEVEL OF 150 TO 1500 CELLS/MCL WITHIN THE PAST 12 MONTHS. EOSINOPHILIC ESOPHAGITIS (EOE): DIAGNOSIS CONFIRMED BY ESOPHAGOGASTRODUODENOSCOPY (EGD) WITH BIOPSY. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: AD, PN, CSU: PRESCRIBED OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED OR IN CONSULTATION WITH ALLERGIST OR PULMONOLOGIST. CRSWNP: PRESCRIBED OR IN CONSULTATION WITH OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOE: PRESCRIBED OR IN CONSULTATION WITH GASTROENTEROLOGIST, ALLERGIST, OR IMMUNOLOGIST. COPD: PRESCRIBED OR IN CONSULTATION WITH PULMONOLOGIST. RENEWAL: CSU: PRESCRIBED OR IN CONSULTATION WITH ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST. |
| Coverage Duration | BP, AFRS: 12 MO. AD/CRSWNP/EOE/PN/CSU: INITIAL/RENEWAL: 6 MO/12 MO. ASTHMA/COPD: INIT/RENEW: 12 MO. |
| Other Criteria | INITIAL: AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE TOPICAL (CORTICOSTEROID, CALCINEURIN INHIBITOR, PDE4 INHIBITOR, OR JAK INHIBITOR). ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY-TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

| PA Criteria | Criteria Details |
|-------------|--|
| | <p>CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS, OR ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 3) INADEQUATELY CONTROLLED DISEASE. PRURIGO NODULARIS (PN): CHRONIC PRURITUS (ITCH MORE THAN 6 WEEKS), MULTIPLE PRURIGINOUS LESIONS, AND HISTORY OR SIGN OF A PROLONGED SCRATCHING BEHAVIOR. EOSINOPHILIC COPD: USED IN COMBINATION WITH A LAMA/LABA/ICS. CHRONIC SPONTANEOUS URTICARIA (CSU): 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. INITIAL/RENEWAL : ALL INDICATIONS EXCEPT BULLOUS PEMPHIGOID (BP): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: AD, CRSWNP, EOE: IMPROVEMENT WHILE ON THERAPY. ASTHMA: 1) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. PN: IMPROVEMENT OR REDUCTION OF PRURITUS OR PRURIGINOUS LESIONS. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, AND 2) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, OR (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-</p> |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | RELATED SYMPTOMS. CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

DUVELISIB

Products Affected

- COPIKTRA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

EFLORNITHINE

Products Affected

- IWILFIN

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ELACESTRANT

Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ELAGOLIX

Products Affected

- ORLISSA ORAL TABLET 150 MG, 200 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS. |
| Age Restrictions | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 18 YEARS OF AGE OR OLDER. |
| Prescriber Restrictions | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS |
| Other Criteria | MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 2) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND A PROGESTIN-CONTAINING PREPARATION. RENEWAL: 1) IMPROVEMENT IN PAIN ASSOCIATED WITH ENDOMETRIOSIS WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

ELAPEGADEMASE-LVLR

Products Affected

- REVCOVI

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | ADENOSINE DEAMINASE SEVERE COMBINED IMMUNE DEFICIENCY (ADA-SCID): INITIAL: ADA-SCID AS MANIFESTED BY: 1) CONFIRMATORY GENETIC TEST, OR 2) SUGGESTIVE LABORATORY FINDINGS (E.G., ELEVATED DEOXYADENOSINE NUCLEOTIDE [DAXP] LEVELS, LYMPHOPENIA) AND HALLMARK SIGNS/SYMPTOMS (E.G., RECURRENT INFECTIONS, FAILURE TO THRIVE, PERSISTENT DIARRHEA). |
| Age Restrictions | |
| Prescriber Restrictions | ADA-SCID: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH IMMUNOLOGIST, HEMATOLOGIST/ONCOLOGIST, OR PHYSICIAN SPECIALIZING IN INHERITED METABOLIC DISORDERS. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | ADA-SCID: RENEWAL: 1) IMPROVEMENT OR MAINTENANCE OF IMMUNE FUNCTION FROM BASELINE, AND 2) HAS NOT RECEIVED SUCCESSFUL HCT OR GENE THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ELEXACFTOR-TEZACFTOR-IVACFTOR

Products Affected

- TRIKAFTA ORAL TABLET THERAPY • TRIKAFTA ORAL THERAPY PACK PACK

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: LIFETIME. |
| Other Criteria | CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ELRANATAMAB-BCMM

Products Affected

- ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RENEWAL: 1) HAS RECEIVED AT LEAST 24 WEEKS OF TREATMENT WITH ELREXFIO, AND 2) HAS RESPONDED TO TREATMENT (PARTIAL RESPONSE OR BETTER), AND HAS MAINTAINED THIS RESPONSE FOR AT LEAST 2 MONTHS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ELTROMBOPAG - ALVAIZ

Products Affected

- ALVAIZ

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT IS LESS THAN $30 \times 10^9/L$, OR 2) PLATELET COUNT IS LESS THAN $50 \times 10^9/L$ AND HAD A PRIOR BLEEDING EVENT. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST. |
| Coverage Duration | ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO. |
| Other Criteria | INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS). RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNT FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ELTROMBOPAG - PROMACTA

Products Affected

- *eltrombopag olamine oral packet 12.5 mg, 25 mg*
- *eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT OF LESS THAN 30 X 10 ⁹ /L, OR 2) PLATELET COUNT OF LESS THAN 50 X 10 ⁹ /L AND A PRIOR BLEEDING EVENT. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST. |
| Coverage Duration | ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO. |
| Other Criteria | INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR HAD AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS). ALL INDICATIONS: ELTROMBOPAG ORAL SUSPENSION PACKETS: TRIAL OF A FORMULARY VERSION OF ELTROMBOPAG TABLET OR PATIENT IS UNABLE TO TOLERATE TABLET FORMULATION. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNTS FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

ENASIDENIB

Products Affected

- IDHIFA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ENCORAFENIB

Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ENSARTINIB

Products Affected

- ENSACOVE ORAL CAPSULE 100 MG, 25 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ENTRECTINIB CAPSULES

Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ENTRECTINIB PELLETS

Products Affected

- ROZLYTREK ORAL PACKET

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), SOLID TUMORS: 1) TRIAL OF OR CONTRAINDICATION TO ROZLYTREK CAPSULES MADE INTO AN ORAL SUSPENSION, AND 2) DIFFICULTY OR UNABLE TO SWALLOW CAPSULES. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ENZALUTAMIDE

Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC): HIGH RISK FOR METASTASIS (I.E. PSA DOUBLING TIME OF 9 MONTHS OR LESS). METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), NON-METASTATIC CRPC (NMCRPC), METASTATIC CSPC (MCSPC), NMCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

EPCORITAMAB-BYSP

Products Affected

- EPKINLY

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

EPOETIN ALFA-EPBX

Products Affected

- RETACRIT INJECTION SOLUTION UNIT/ML, 4000 UNIT/ML, 40000
10000 UNIT/ML, 10000 UNIT/ML(1ML), UNIT/ML
2000 UNIT/ML, 20000 UNIT/ML, 3000

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: CHRONIC KIDNEY DISEASE (CKD), ANEMIA RELATED TO ZIDOVUDINE, OR CANCER CHEMOTHERAPY: HEMOGLOBIN LEVEL IS LESS THAN 10G/DL. ELECTIVE, NON-CARDIAC, NON-VASCULAR SURGERY: HEMOGLOBIN LEVEL IS 13G/DL OR LESS. RENEWAL: 1) CKD IN ADULTS NOT ON DIALYSIS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS REACHED 10G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 2) CKD IN PEDIATRIC PATIENTS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS APPROACHED OR EXCEEDS 12G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 3) ANEMIA RELATED TO ZIDOVUDINE: HEMOGLOBIN LEVEL BETWEEN 10G/DL AND 12G/DL. 4) CANCER CHEMOTHERAPY: (A) HEMOGLOBIN LEVEL IS LESS THAN 10 G/DL, OR (B) HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | ANEMIA FROM CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE: INITIAL/RENEWAL: 12 MONTHS. SURGERY: 1 MONTH. |
| Other Criteria | RENEWAL: CKD: NOT RECEIVING DIALYSIS TREATMENT. THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ERDAFITINIB

Products Affected

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ERENUMAB-AOOE

Products Affected

- AIMOVIG

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ERLOTINIB

Products Affected

- *erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg*

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ESKETAMINE

Products Affected

- SPRAVATO (56 MG DOSE)
- SPRAVATO (84 MG DOSE)

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: TREATMENT-RESISTANT DEPRESSION (TRD), MAJOR DEPRESSIVE DISORDER (MDD): PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST OR OTHER REMS-CERTIFIED PROVIDER. |
| Coverage Duration | INITIAL: TRD: 3 MONTHS. MDD: 4 WEEKS. RENEWAL: TRD, MDD: 12 MONTHS. |
| Other Criteria | INITIAL: TRD, MDD: 1) NON-PSYCHOTIC, UNIPOLAR DEPRESSION, AND 2) NO ACTIVE SUBSTANCE ABUSE. RENEWAL: TRD, MDD: DEMONSTRATED CLINICAL BENEFIT (IMPROVEMENT IN DEPRESSION) COMPARED TO BASELINE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ETANERCEPT

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | <p>SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

EVEROLIMUS-AFINITOR

Products Affected

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

EVEROLIMUS-AFINITOR DISPERZ

Products Affected

- *everolimus oral tablet soluble*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

FECAL MICROBIOTA CAPSULE

Products Affected

- VOWST

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 30 DAYS |
| Other Criteria | CLOSTRIDIODES DIFFICILE INFECTION (CDI): 1) HAS NOT PREVIOUSLY RECEIVED VOWST: COMPLETION OF ANTIBIOTIC TREATMENT FOR RECURRENT CDI (AT LEAST 3 CDI EPISODES), OR 2) PREVIOUSLY RECEIVED VOWST: (A) TREATMENT FAILURE (DEFINED AS THE PRESENCE OF CDI DIARRHEA WITHIN 8 WEEKS OF FIRST DOSE OF VOWST AND A POSITIVE STOOL TEST FOR C. DIFFICILE), AND (B) HAS NOT RECEIVED MORE THAN ONE TREATMENT COURSE OF VOWST WHICH WAS AT LEAST 12 DAYS AND NOT MORE THAN 8 WEEKS PRIOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

FEDRATINIB

Products Affected

- INREBIC

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | MYELOFIBROSIS: INITIAL: TRIAL OF OR CONTRAINDICATION TO JAKAFI (RUXOLITINIB). RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

FENFLURAMINE

Products Affected

- FINTEPLA

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: DRAVET SYNDROME, LENNOX-GASTAUT SYNDROME (LGS): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

FENTANYL CITRATE

Products Affected

- *fentanyl citrate buccal lozenge on a handle*

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | CANCER RELATED PAIN: 1) CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION, AND 2) TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT OR PATIENT HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

FEZOLINETANT

Products Affected

- VEOZAH

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | MENOPAUSAL VASOMOTOR SYMPTOMS (VMS): INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO HORMONAL THERAPY (E.G., ESTRADIOL TRANSDERMAL PATCH, ORAL CONJUGATED ESTROGENS), 2) LABORATORY TESTING TO ESTABLISH BASELINE HEPATIC FUNCTION AND CONTINUED MONITORING OF THESE VALUES IN ACCORDANCE WITH THE FDA CURRENT LABEL RECOMMENDATION, AND 3) NO CONCURRENT USE WITH ANOTHER HORMONAL (E.G., PREMPRO) OR NON-HORMONAL (E.G., BRISDELLE) AGENT FOR VMS. RENEWAL: 1) CONTINUED NEED FOR VMS TREATMENT (PERSISTENT HOT FLASHES), 2) REDUCTION IN VMS FREQUENCY OR SEVERITY DUE TO VEOZAH TREATMENT, AND 3) NO NEW SYMPTOMS OF LIVER INJURY AND/OR WORSENING LAB VALUES (E.G., ALT, AST, TOTAL BILIRUBIN). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

FILGRASTIM-AAFI

Products Affected

- NIVESTYM

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

FINERENONE

Products Affected

- KERENDIA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: HEART FAILURE (HF): 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS II-IV, AND 2) LEFT VENTRICULAR EJECTION FRACTION OF AT LEAST 40 PERCENT NOT DUE TO AN UNDERLYING CAUSE (E.G., INFILTRATIVE CARDIOMYOPATHY, HYPERTROPHIC CARDIOMYOPATHY, VALVULAR DISEASE, PERICARDIAL DISEASE, HIGH-OUTPUT HEART FAILURE). |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: HF: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL:12 MONTHS |
| Other Criteria | CHRONIC KIDNEY DISEASE (CKD) ASSOCIATED WITH TYPE 2 DIABETES (T2D): INITIAL: HISTORY OF AND WILL CONTINUE ON, HAS A CONTRAINDICATION, OR INTOLERANCE TO AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE-I) OR AN ANGIOTENSIN RECEPTOR BLOCKER (ARB). HF: INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER MINERALOCORTICOID (ALDOSTERONE) RECEPTOR ANTAGONIST. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

FINGOLIMOD

Products Affected

- *fingolimod hcl*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

FOSCARBIDOPA-FOSLEVODOPA

Products Affected

- VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL: 12 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | PD: INITIAL: ONE OF THE FOLLOWING: 1) UNABLE TO SWALLOW EXTENDED-RELEASE (ER) TABLETS OR ADMINISTER ER CAPSULES VIA A FEEDING TUBE, OR 2) FAILURE TO ADHERE OR TOLERATE VIA A FEEDING TUBE AN ORAL CARBIDOPA/LEVODOPA REGIMEN. RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

FRUQUINTINIB

Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

FUTIBATINIB

Products Affected

- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA): COMPLETE A COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

GALCANEZUMAB-GNLM

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: MIGRAINE PREVENTION: 6 MOS. EPISODIC CLUSTER HEADACHE: 3 MOS. RENEWAL (ALL): 12 MOS. |
| Other Criteria | MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. EPISODIC CLUSTER HEADACHE: RENEWAL: IMPROVEMENT IN EPISODIC CLUSTER HEADACHE FREQUENCY AS COMPARED TO BASELINE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

GANAXOLONE

Products Affected

- ZTALMY

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

GEFITINIB

Products Affected

- *gefitinib*

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

GEPHIRONE

Products Affected

- EXXUA
- EXXUA TITRATION PACK

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | MAJOR DEPRESSIVE DISORDER: INITIAL: TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENTS: TRINTELLIX AND ONE GENERIC ANTIDEPRESSANT. INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER 5-HT1A RECEPTOR AGONIST (E.G., BUSPIRONE). RENEWAL: RESPONSE TO OR REMISSION OF DEPRESSIVE SYMPTOMS WITH THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

GILTERITINIB

Products Affected

- XOSPATA

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

GLASDEGIB

Products Affected

- DAURISMO ORAL TABLET 100 MG,
25 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

GLATIRAMER

Products Affected

- *glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*
- *glatopa subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

GLECAPREVIR/PIBRENTASVIR

Products Affected

- MAVYRET ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | HCV RNA LEVEL WITHIN PAST 6 MONTHS |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. |
| Other Criteria | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) INTOLERANCE OR CONTRAINDICATION TO ONE OF THE PREFERRED FORMULARY AGENTS: HARVONI OR EPCLUSA, WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE, 3) NO CONCURRENT USE WITH THE FOLLOWING AGENTS: RIFAMPIN, ATAZANAVIR, CARBAMAZEPINE, EFAVIRENZ, DARUNAVIR, LOPINAVIR, RITONAVIR, ATORVASTATIN, LOVASTATIN, SIMVASTATIN, ROSUVASTATIN AT DOSES GREATER THAN 10MG, CYCLOSPORINE AT DOSES GREATER THAN 100MG PER DAY, MEDICATIONS CONTAINING MORE THAN 20MCG OF ETHINYL ESTRADIOL, EPCLUSA, HARVONI, VOSEVI, OR ZEPATIER, AND 4) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD PUGH B OR C). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

GLP1-DULAGLUTIDE

Products Affected

- TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

GLP1-SEMAGLUTIDE

Products Affected

- OZEMPIC
 - OZEMPIC (0.25 OR 0.5 MG/DOSE)
 - OZEMPIC (1 MG/DOSE)
 - OZEMPIC (2 MG/DOSE)
 - RYBELSUS
 - RYBELSUS (FORMULATION R2)
- SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

GLP1-TIRZEPATIDE

Products Affected

- MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS. |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

GOSERELIN

Products Affected

- ZOLADEX

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS. |
| Age Restrictions | |
| Prescriber Restrictions | ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST. |
| Coverage Duration | STAGE B2-C PROSTATIC CARCINOMA: 4 MOS. ENDOMETRIOSIS: 6 MOS PER LIFETIME. ALL OTHERS: 12 MONTHS. |
| Other Criteria | ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 6 MONTHS OF TREATMENT PER LIFETIME. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

GUSELKUMAB

Products Affected

- TREMFYA INTRAVENOUS
- TREMFYA ONE-PRESS SUBCUTANEOUS SOLUTION PEN-INJECTOR
- TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML
- TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- TREMFYA-CD/UC INDUCTION

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| | SAME INDICATION. RENEWAL: PSO, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

IBRUTINIB

Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | CHRONIC GRAFT VS HOST DISEASE (CGVHD): NO CONCURRENT USE WITH JAKAFI, NIKTIMVO, OR REZUROCK. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ICATIBANT

Products Affected

- *icatibant acetate*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | HEREDITARY ANGIOEDEMA (HAE): INITIAL: 1) TYPE III HAE, OR 2) TYPE I OR II HAE CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTS: C1-INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q. |
| Age Restrictions | |
| Prescriber Restrictions | HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, IMMUNOLOGIST, HEMATOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | HAE: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER MEDICATIONS FOR THE TREATMENT OF ACUTE HAE ATTACKS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

IDELALISIB

Products Affected

- ZYDELIG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

IMATINIB

Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS. |
| Other Criteria | PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

IMATINIB SOLUTION

Products Affected

- IMKELDI

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS. |
| Other Criteria | PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. ALL INDICATIONS: UNABLE TO SWALLOW GENERIC IMATINIB TABLETS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

IMETELSTAT

Products Affected

- RYTELO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

IMLUNESTRANT

Products Affected

- INLURIYO

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

INAVOLISIB

Products Affected

- ITOVEBI ORAL TABLET 3 MG, 9 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

INFLIXIMAB

Products Affected

- infliximab*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA. PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, SKYRIZI, TREMFYA, OTEZLA. AS: TRIAL OF OR CONTRAINDICATION TO |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | <p>TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ. MODERATE TO SEVERE CD: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, RINVOQ, SKYRIZI, TREMFYA. UC: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, XELJANZ, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, RINVOQ, SKYRIZI, TREMFYA. INITIAL/RENEWAL: RA, PSA, AS, PSO, MODERATE TO SEVERE CD, UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

INSULIN SUPPLIES PAYMENT DETERMINATION

Products Affected

- ABOUTTIME PEN NEEDLE 30G X 8 MM
- ABOUTTIME PEN NEEDLE 31G X 5 MM
- ABOUTTIME PEN NEEDLE 31G X 8 MM
- ABOUTTIME PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLES 29G X 12.7MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 5 MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 8 MM
- ADVOCATE INSULIN PEN NEEDLES 33G X 4 MM
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 1 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 1 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 1 ML
- ALCOHOL PREP PAD
- ALCOHOL PREP PAD 70 %
- ALCOHOL PREP PADS PAD 70 %
- ALCOHOL SWABS PAD
- ALCOHOL SWABS PAD 70 %
- AQ INSULIN SYRINGE 31G X 5/16" 1 ML
- AQINJECT PEN NEEDLE 31G X 5 MM
- AQINJECT PEN NEEDLE 32G X 4 MM
- ASSURE ID DUO PRO PEN NEEDLES 31G X 5 MM
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 0.5 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 1 ML
- ASSURE ID PRO PEN NEEDLES 30G X 5 MM
- AUM ALCOHOL PREP PADS PAD 70 %
- AUM INSULIN SAFETY PEN NEEDLE 31G X 4 MM
- AUM INSULIN SAFETY PEN NEEDLE 31G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 6 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 8 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 5 MM

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- AUM MINI INSULIN PEN NEEDLE 33G X 6 MM
- AUM PEN NEEDLE 32G X 4 MM
- AUM PEN NEEDLE 32G X 5 MM
- AUM PEN NEEDLE 32G X 6 MM
- AUM PEN NEEDLE 33G X 4 MM
- AUM PEN NEEDLE 33G X 5 MM
- AUM PEN NEEDLE 33G X 6 MM
- AUM READYGARD DUO PEN NEEDLE 32G X 4 MM
- AUM SAFETY PEN NEEDLE 31G X 4 MM
- AURORA PEN NEEDLES 29G X 12MM
- AURORA PEN NEEDLES 31G X 6 MM
- AURORA PEN NEEDLES 31G X 8 MM
- BD AUTOSHIELD DUO 30G X 5 MM
- BD ECLIPSE SYRINGE 30G X 1/2" 1 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.3 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.5 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 1 ML
- BD INSULIN SYRINGE 27.5G X 5/8" 2 ML
- BD INSULIN SYRINGE 27G X 1/2" 1 ML
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (RX)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE HALF-UNIT 31G X 5/16" 0.3 ML
- BD INSULIN SYRINGE MICROFINE 27G X 5/8" 1 ML
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE U-100 1 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.5 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.5 ML
- BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM
- BD PEN NEEDLE MINI U/F 31G X 5 MM
- BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM
- BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM
- BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM
- BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM
- BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 1 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8" 1 ML
- BD SWAB SINGLE USE REGULAR PAD
- BD SWABS SINGLE USE BUTTERFLY PAD

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.5 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 1 ML
- CAREFINE PEN NEEDLES 29G X 12MM
- CAREFINE PEN NEEDLES 30G X 8 MM
- CAREFINE PEN NEEDLES 31G X 6 MM
- CAREFINE PEN NEEDLES 31G X 8 MM
- CAREFINE PEN NEEDLES 32G X 4 MM
- CAREFINE PEN NEEDLES 32G X 5 MM
- CAREFINE PEN NEEDLES 32G X 6 MM
- CAREONE INSULIN SYRINGE 30G X 1/2" 0.3 ML
- CAREONE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- CAREONE INSULIN SYRINGE 30G X 1/2" 1 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 1 ML
- CARETOUCH ALCOHOL PREP PAD 70 %
- CARETOUCH INSULIN SYRINGE 28G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 29G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- CARETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- CARETOUCH PEN NEEDLES 29G X 12MM
- CARETOUCH PEN NEEDLES 31G X 5 MM
- CARETOUCH PEN NEEDLES 31G X 6 MM
- CARETOUCH PEN NEEDLES 31G X 8 MM
- CARETOUCH PEN NEEDLES 32G X 4 MM
- CARETOUCH PEN NEEDLES 32G X 5 MM
- CARETOUCH PEN NEEDLES 33G X 4 MM
- CLEVER CHOICE COMFORT EZ 29G X 12MM
- CLEVER CHOICE COMFORT EZ 33G X 4 MM
- CLICKFINE PEN NEEDLES 31G X 8 MM
- CLICKFINE PEN NEEDLES 32G X 4 MM
- COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML
- COMFORT ASSIST INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 27G X 1/2" 1 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- COMFORT EZ INSULIN SYRINGE 28G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 28G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 1 ML
- COMFORT EZ PEN NEEDLES 31G X 5 MM
- COMFORT EZ PEN NEEDLES 31G X 6 MM
- COMFORT EZ PEN NEEDLES 31G X 8 MM
- COMFORT EZ PEN NEEDLES 32G X 4 MM
- COMFORT EZ PEN NEEDLES 32G X 5 MM
- COMFORT EZ PEN NEEDLES 32G X 6 MM
- COMFORT EZ PEN NEEDLES 32G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 30G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 4 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM
- CURITY ALCOHOL PREPS PAD 70 %
- CURITY ALL PURPOSE SPONGES PAD 2"X2"
- CURITY GAUZE PAD 2"X2"
- CURITY GAUZE SPONGE PAD 2"X2"
- CURITY SPONGES PAD 2"X2"
- CVS ALCOHOL PREP PADS PAD 70 %

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- CVS GAUZE PAD 2"X2"
- CVS GAUZE STERILE PAD 2"X2"
- *cvs isopropyl alcohol wipes*
- CVS PREP PAD 70 %
- DERMACEA GAUZE SPONGE PAD 2"X2"
- DERMACEA IV DRAIN SPONGES PAD 2"X2"
- DERMACEA NON-WOVEN SPONGES PAD 2"X2"
- DERMACEA TYPE VII GAUZE PAD 2"X2"
- DIATHRIVE PEN NEEDLE 31G X 5 MM
- DIATHRIVE PEN NEEDLE 31G X 6 MM
- DIATHRIVE PEN NEEDLE 31G X 8 MM
- DIATHRIVE PEN NEEDLE 32G X 4 MM
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 1 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 1 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X 5/16" 1 ML
- DROPLET MICRON 34G X 3.5 MM
- DROPLET PEN NEEDLES 29G X 10MM
- DROPLET PEN NEEDLES 29G X 12MM
- DROPLET PEN NEEDLES 30G X 8 MM
- DROPLET PEN NEEDLES 31G X 5 MM
- DROPLET PEN NEEDLES 31G X 6 MM
- DROPLET PEN NEEDLES 31G X 8 MM
- DROPLET PEN NEEDLES 32G X 4 MM
- DROPLET PEN NEEDLES 32G X 5 MM
- DROPLET PEN NEEDLES 32G X 6 MM
- DROPLET PEN NEEDLES 32G X 8 MM
- DROPSAFE ALCOHOL PREP PAD 70 %
- DROPSAFE AUTOPROTECT DUO 31G X 4 MM
- DROPSAFE AUTOPROTECT DUO 31G X 8 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 5 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 6 MM
- DROPSAFE SAFETY SYRINGE/NEEDLE 29G X 1/2" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.3 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 1 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.3 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.5 ML
- DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 1 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 0.3 ML
- DRUG MART ULTRA COMFORT SYR 29G X 1/2" 1 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 0.5 ML
- DRUG MART ULTRA COMFORT SYR 30G X 5/16" 1 ML
- DRUG MART UNIFINE PENTIPS 31G X 5 MM
- EASY COMFORT ALCOHOL PADS PAD
- EASY COMFORT INSULIN SYRINGE 29G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 29G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 31G X 1/2" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 0.5 ML
- EASY COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- EASY COMFORT PEN NEEDLES 29G X 4MM
- EASY COMFORT PEN NEEDLES 29G X 5MM
- EASY COMFORT PEN NEEDLES 31G X 5 MM
- EASY COMFORT PEN NEEDLES 31G X 6 MM
- EASY COMFORT PEN NEEDLES 31G X 8 MM
- EASY COMFORT PEN NEEDLES 32G X 4 MM
- EASY COMFORT PEN NEEDLES 33G X 4 MM
- EASY COMFORT PEN NEEDLES 33G X 5 MM
- EASY COMFORT PEN NEEDLES 33G X 6 MM
- EASY GLIDE PEN NEEDLES 33G X 4 MM
- EASY TOUCH ALCOHOL PREP MEDIUM PAD 70 %
- EASY TOUCH FLIPLOCK INSULIN SY 29G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 31G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK SAFETY SYR 27G X 1/2" 1 ML
- EASY TOUCH INSULIN BARRELS U-100 1 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 1 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- EASY TOUCH INSULIN SAFETY SYR 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SAFETY SYR 30G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 27G X 5/8" 1 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY TOUCH PEN NEEDLES 29G X 12MM
- EASY TOUCH PEN NEEDLES 30G X 5 MM
- EASY TOUCH PEN NEEDLES 30G X 6 MM
- EASY TOUCH PEN NEEDLES 30G X 8 MM
- EASY TOUCH PEN NEEDLES 31G X 5 MM
- EASY TOUCH PEN NEEDLES 31G X 6 MM
- EASY TOUCH PEN NEEDLES 31G X 8 MM
- EASY TOUCH PEN NEEDLES 32G X 4 MM
- EASY TOUCH PEN NEEDLES 32G X 5 MM
- EASY TOUCH PEN NEEDLES 32G X 6 MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM
- EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM
- EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16" 1 ML
- EMBECTA AUTOSHIELD DUO 30G X 5 MM
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64" 0.3 ML
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 1 ML
- EMBECTA INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EMBECTA INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)
- EMBECTA INSULIN SYRINGE U-100 27G X 5/8" 1 ML
- EMBECTA INSULIN SYRINGE U-500
- EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM
- EMBECTA PEN NEEDLE NANO 32G X 4 MM
- EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM
- EMBECTA PEN NEEDLE ULTRAFINE 31G X 5 MM
- EMBECTA PEN NEEDLE ULTRAFINE 31G X 8 MM
- EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM
- EMBRACE PEN NEEDLES 29G X 12MM
- EMBRACE PEN NEEDLES 30G X 5 MM
- EMBRACE PEN NEEDLES 30G X 8 MM
- EMBRACE PEN NEEDLES 31G X 5 MM
- EMBRACE PEN NEEDLES 31G X 6 MM
- EMBRACE PEN NEEDLES 31G X 8 MM
- EMBRACE PEN NEEDLES 32G X 4 MM
- EQL ALCOHOL SWABS PAD 70 %
- EQL GAUZE PAD 2"X2"
- EQL INSULIN SYRINGE 30G X 5/16" 1 ML
- EXEL COMFORT POINT INSULIN SYR 29G X 1/2" 0.3 ML
- EXEL COMFORT POINT INSULIN SYR 30G X 5/16" 0.3 ML
- EXEL COMFORT POINT PEN NEEDLE 29G X 12MM
- FIFTY50 PEN NEEDLES 31G X 5 MM
- FIFTY50 PEN NEEDLES 31G X 8 MM
- FIFTY50 PEN NEEDLES 32G X 4 MM
- FIFTY50 PEN NEEDLES 32G X 6 MM
- GAUZE PADS PAD 2"X2"
- GAUZE TYPE VII MEDI-PAK PAD 2"X2"
- GLOBAL ALCOHOL PREP EASE
- GLOBAL EASE INJECT PEN NEEDLES 29G X 12MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 5 MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 8 MM
- GLOBAL EASE INJECT PEN NEEDLES 32G X 4 MM
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.3 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.5 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 1 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 1 ML
- GNP ALCOHOL SWABS PAD
- GNP CLICKFINE PEN NEEDLES 31G X 6 MM
- GNP CLICKFINE PEN NEEDLES 31G X 8 MM
- GNP INSULIN SYRINGE 28G X 1/2" 1 ML
- GNP INSULIN SYRINGE 29G X 1/2" 1 ML
- GNP INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GNP INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 0.5 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 1 ML
- GNP INSULIN SYRINGES 30G X 5/16" 1 ML
- GNP INSULIN SYRINGES 30GX5/16" 30G X 5/16" 0.3 ML
- GNP INSULIN SYRINGES 31GX5/16" 31G X 5/16" 0.3 ML
- GNP PEN NEEDLES 31G X 5 MM
- GNP PEN NEEDLES 32G X 4 MM
- GNP PEN NEEDLES 32G X 6 MM
- GNP STERILE GAUZE PAD 2"X2"
- GNP ULTRA COM INSULIN SYRINGE 29G X 1/2" 0.5 ML
- GNP ULTRA COM INSULIN SYRINGE 30G X 5/16" 1 ML
- GOODSENSE ALCOHOL SWABS PAD 70 %
- GOODSENSE CLICKFINE PEN NEEDLE 31G X 5 MM
- GOODSENSE PEN NEEDLE PENFINE 31G X 8 MM
- H-E-B INCONTROL ALCOHOL PAD
- H-E-B INCONTROL PEN NEEDLES 29G X 12MM
- H-E-B INCONTROL PEN NEEDLES 31G X 5 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 6 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 8 MM
- H-E-B INCONTROL PEN NEEDLES 32G X 4 MM
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 1 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 1 ML
- HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM
- HM STERILE ALCOHOL PREP PAD
- HM STERILE PADS PAD 2"X2"
- HM ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- HM ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM
- INSULIN SYRINGE 29G X 1/2" 0.3 ML
- INSULIN SYRINGE 29G X 1/2" 0.5 ML
- INSULIN SYRINGE 29G X 1/2" 1 ML
- INSULIN SYRINGE 30G X 5/16" 0.3 ML
- INSULIN SYRINGE 30G X 5/16" 0.5 ML
- INSULIN SYRINGE 30G X 5/16" 1 ML
- INSULIN SYRINGE 31G X 5/16" 0.3 ML
- INSULIN SYRINGE 31G X 5/16" 0.5 ML
- INSULIN SYRINGE 31G X 5/16" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.3 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.5 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 5/16" 0.5 ML (OTC)
- INSULIN SYRINGE/NEEDLE 27G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 1 ML
- INSUPEN PEN NEEDLES 29G X 12MM
- INSUPEN PEN NEEDLES 31G X 5 MM
- INSUPEN PEN NEEDLES 31G X 8 MM
- INSUPEN PEN NEEDLES 32G X 4 MM
- INSUPEN PEN NEEDLES 33G X 4 MM
- INSUPEN SENSITIVE 32G X 6 MM
- INSUPEN SENSITIVE 32G X 8 MM
- INSUPEN ULTRAFIN 30G X 8 MM
- INSUPEN ULTRAFIN 31G X 6 MM
- INSUPEN ULTRAFIN 31G X 8 MM
- INSUPEN32G EXTR3ME 32G X 6 MM
- J & J GAUZE PAD 2"X2"
- KENDALL HYDROPHILIC FOAM DRESS PAD 2"X2"
- KENDALL HYDROPHILIC FOAM PLUS PAD 2"X2"
- KINRAY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- KMART VALU INSULIN SYRINGE 29G U-100 1 ML
- KMART VALU INSULIN SYRINGE 30G U-100 0.3 ML
- KMART VALU INSULIN SYRINGE 30G U-100 1 ML
- KROGER INSULIN SYRINGE 30G X 5/16" 0.5 ML
- KROGER PEN NEEDLES 29G X 12MM
- KROGER PEN NEEDLES 31G X 6 MM
- LEADER INSULIN SYRINGE 28G X 1/2" 0.5 ML
- LEADER INSULIN SYRINGE 28G X 1/2" 1 ML
- LEADER UNIFINE PENTIPS 31G X 5 MM
- LEADER UNIFINE PENTIPS 32G X 4 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 5 MM

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- LEADER UNIFINE PENTIPS PLUS 31G X 8 MM
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.3 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- LITETOUCH PEN NEEDLES 29G X 12.7MM
- LITETOUCH PEN NEEDLES 31G X 5 MM
- LITETOUCH PEN NEEDLES 31G X 6 MM
- LITETOUCH PEN NEEDLES 31G X 8 MM
- LITETOUCH PEN NEEDLES 32G X 4 MM
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 1 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 1 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM
- MAXICOMFORT II PEN NEEDLE 31G X 6 MM
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 0.5 ML
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 1 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.5 ML
- MEDICINE SHOPPE PEN NEEDLES 29G X 12MM
- MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM
- MEDPURA ALCOHOL PADS 70 % EXTERNAL
- MEIJER ALCOHOL SWABS PAD 70 %
- MEIJER PEN NEEDLES 29G X 12MM
- MEIJER PEN NEEDLES 31G X 6 MM
- MEIJER PEN NEEDLES 31G X 8 MM
- MICRODOT PEN NEEDLE 31G X 6 MM
- MICRODOT PEN NEEDLE 32G X 4 MM
- MICRODOT PEN NEEDLE 33G X 4 MM
- MIRASORB SPONGES 2"X2"
- MM PEN NEEDLES 31G X 6 MM
- MM PEN NEEDLES 32G X 4 MM
- MONOJECT INSULIN SYRINGE 25G X 5/8" 1 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- MONOJECT INSULIN SYRINGE 27G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 31G X 5/16" 1 ML
- MONOJECT INSULIN SYRINGE U-100 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.5 ML (RX)
- MS INSULIN SYRINGE 31G X 5/16" 0.3 ML
- MS INSULIN SYRINGE 31G X 5/16" 0.5 ML
- NOVOFINE AUTOCOVER 30G X 8 MM
- NOVOFINE PEN NEEDLE 32G X 6 MM
- NOVOFINE PLUS PEN NEEDLE 32G X 4 MM
- NOVOTWIST PEN NEEDLE 32G X 5 MM
- PC UNIFINE PENTIPS 31G X 5 MM
- PC UNIFINE PENTIPS 31G X 6 MM
- PC UNIFINE PENTIPS 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 31G X 8 MM
- PEN NEEDLES 30G X 5 MM (OTC)
- PEN NEEDLES 30G X 8 MM
- PEN NEEDLES 32G X 5 MM
- PENTIPS 29G X 12MM (RX)
- PENTIPS 31G X 5 MM (RX)
- PENTIPS 31G X 8 MM (RX)
- PENTIPS 32G X 4 MM (RX)
- PENTIPS GENERIC PEN NEEDLES 29G X 12MM
- PENTIPS GENERIC PEN NEEDLES 31G X 6 MM
- PENTIPS GENERIC PEN NEEDLES 32G X 6 MM
- PHARMACIST CHOICE ALCOHOL PAD
- PIP PEN NEEDLES 31G X 5MM 31G X 5 MM
- PIP PEN NEEDLES 32G X 4MM 32G X 4 MM
- PRECISION SURE-DOSE SYRINGE 30G X 5/16" 0.3 ML
- PREFERRED PLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 1 ML
- PREFERRED PLUS INSULIN SYRINGE 30G X 5/16" 1 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM
- PREVENT SAFETY PEN NEEDLES 31G X 6 MM
- PREVENT SAFETY PEN NEEDLES 31G X 8 MM
- PRO COMFORT ALCOHOL PAD 70 %
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- PRO COMFORT PEN NEEDLES 32G X 4 MM
- PRO COMFORT PEN NEEDLES 32G X 5 MM
- PRO COMFORT PEN NEEDLES 32G X 6 MM
- PRO COMFORT PEN NEEDLES 32G X 8 MM
- PRODIGY INSULIN SYRINGE 28G X 1/2" 1 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.3 ML
- PRODIGY INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PURE COMFORT ALCOHOL PREP PAD
- PURE COMFORT PEN NEEDLE 32G X 4 MM
- PURE COMFORT PEN NEEDLE 32G X 5 MM
- PURE COMFORT PEN NEEDLE 32G X 6 MM
- PURE COMFORT PEN NEEDLE 32G X 8 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM
- PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM
- PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM
- PX SHORTLENGTH PEN NEEDLES 31G X 8 MM
- QC ALCOHOL
- QC ALCOHOL SWABS PAD 70 %
- QC BORDER ISLAND GAUZE PAD 2"X2"
- QUICK TOUCH INSULIN PEN NEEDLE 29G X 12.7MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 8 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM
- RA ALCOHOL SWABS PAD 70 %

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- RA INSULIN SYRINGE 29G X 1/2" 0.5 ML
- RA INSULIN SYRINGE 29G X 1/2" 1 ML
- RA INSULIN SYRINGE 30G X 5/16" 0.5 ML
- RA INSULIN SYRINGE 30G X 5/16" 1 ML
- *ra isopropyl alcohol wipes*
- RA PEN NEEDLES 31G X 5 MM
- RA PEN NEEDLES 31G X 8 MM
- RA STERILE PAD 2"X2"
- RAYA SURE PEN NEEDLE 29G X 12MM
- RAYA SURE PEN NEEDLE 31G X 4 MM
- RAYA SURE PEN NEEDLE 31G X 5 MM
- RAYA SURE PEN NEEDLE 31G X 6 MM
- RAYA SURE PEN NEEDLE 31G X 8 MM
- REALITY INSULIN SYRINGE 28G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 28G X 1/2" 1 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 1 ML
- REALITY SWABS PAD
- RELI-ON INSULIN SYRINGE 29G 0.3 ML
- RELION ALCOHOL SWABS PAD
- RELION ALCOHOL SWABS PAD 70 %
- RELION INSULIN SYRINGE 31G X 15/64" 0.3 ML
- RELION INSULIN SYRINGE 31G X 15/64" 0.5 ML
- RELION INSULIN SYRINGE 31G X 15/64" 1 ML
- RELION MINI PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 29G X 12MM
- RELION PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 8 MM
- RESTORE CONTACT LAYER PAD 2"X2"
- SAFETY INSULIN SYRINGES 29G X 1/2" 0.5 ML
- SAFETY INSULIN SYRINGES 29G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 5/16" 0.5 ML
- SAFETY PEN NEEDLES 30G X 5 MM
- SAFETY PEN NEEDLES 30G X 8 MM
- SB ALCOHOL PREP PAD 70 %
- SB INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SB INSULIN SYRINGE 29G X 1/2" 1 ML
- SB INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SB INSULIN SYRINGE 30G X 5/16" 1 ML
- SB INSULIN SYRINGE 31G X 5/16" 1 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 1 ML
- SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM
- SM ALCOHOL PREP PAD
- SM ALCOHOL PREP PAD 6-70 % EXTERNAL
- SM ALCOHOL PREP PAD 70 %
- SM GAUZE PAD 2"X2"
- STERILE GAUZE PAD 2"X2"
- SURE COMFORT ALCOHOL PREP PAD 70 %
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE COMFORT PEN NEEDLES 29G X 12.7MM
- SURE COMFORT PEN NEEDLES 30G X 8 MM
- SURE COMFORT PEN NEEDLES 31G X 5 MM
- SURE COMFORT PEN NEEDLES 31G X 6 MM
- SURE COMFORT PEN NEEDLES 31G X 8 MM
- SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC)
- SURE COMFORT PEN NEEDLES 32G X 4 MM (RX)
- SURE COMFORT PEN NEEDLES 32G X 6 MM
- SURGICAL GAUZE SPONGE PAD 2"X2"
- TECHLITE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- THERAGAUZE PAD 2"X2"
- TODAYS HEALTH PEN NEEDLES 29G X 12MM
- TODAYS HEALTH SHORT PEN NEEDLE 31G X 8 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 1 ML
- TRUE COMFORT ALCOHOL PREP PADS PAD 70 %
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- TRUE COMFORT PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO ALCOHOL PREP PAD 70 %
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 1 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 1 ML
- TRUE COMFORT PRO PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 8 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM
- TRUEPLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 28G X 1/2" 1 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 1 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 31G X 5/16" 1 ML

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- TRUEPLUS PEN NEEDLES 29G X 12MM
- TRUEPLUS PEN NEEDLES 31G X 5 MM
- TRUEPLUS PEN NEEDLES 31G X 6 MM
- TRUEPLUS PEN NEEDLES 31G X 8 MM
- TRUEPLUS PEN NEEDLES 32G X 4 MM
- ULTICARE INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- ULTICARE INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 28G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 28G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (OTC)
- ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- ULTICARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 0.3 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 0.5 ML
- ULTICARE INSULIN SYRINGE 31G X 1/4" 1 ML
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (OTC)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (RX)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (OTC)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (RX)
- ULTICARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTICARE MICRO PEN NEEDLES 32G X 4 MM
- ULTICARE MINI PEN NEEDLES 30G X 5 MM
- ULTICARE MINI PEN NEEDLES 31G X 6 MM
- ULTICARE MINI PEN NEEDLES 32G X 6 MM
- ULTICARE PEN NEEDLES 29G X 12.7MM (OTC)
- ULTICARE PEN NEEDLES 29G X 12.7MM (RX)
- ULTICARE PEN NEEDLES 31G X 5 MM
- ULTICARE SHORT PEN NEEDLES 30G X 8 MM
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC)
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX)
- ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM
- ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 0.3 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 0.5 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2" 1 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 0.3 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 0.5 ML
- ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16" 1 ML
- ULTILET ALCOHOL SWABS PAD
- ULTILET PEN NEEDLE 29G X 12.7MM
- ULTILET PEN NEEDLE 31G X 5 MM
- ULTILET PEN NEEDLE 31G X 8 MM
- ULTILET PEN NEEDLE 32G X 4 MM
- ULTRA COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM
- ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM
- ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM
- ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRA THIN PEN NEEDLES 32G X 4 MM
- ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 1 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 1 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM
- ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM
- ULTRA-THIN II PEN NEEDLES 29G X 12.7MM

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- ULTRACARE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRACARE PEN NEEDLES 31G X 5 MM
- ULTRACARE PEN NEEDLES 31G X 6 MM
- ULTRACARE PEN NEEDLES 31G X 8 MM
- ULTRACARE PEN NEEDLES 32G X 4 MM
- ULTRACARE PEN NEEDLES 32G X 5 MM
- ULTRACARE PEN NEEDLES 32G X 6 MM
- ULTRACARE PEN NEEDLES 33G X 4 MM
- UNIFINE OTC PEN NEEDLES 31G X 5 MM
- UNIFINE OTC PEN NEEDLES 32G X 4 MM
- UNIFINE PEN NEEDLES 32G X 4 MM
- UNIFINE PENTIPS 29G X 12MM
- UNIFINE PENTIPS 31G X 6 MM
- UNIFINE PENTIPS 31G X 8 MM
- UNIFINE PENTIPS 32G X 4 MM
- UNIFINE PENTIPS PLUS 29G X 12MM
- UNIFINE PENTIPS PLUS 31G X 6 MM
- UNIFINE PENTIPS PLUS 32G X 4 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 5 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 8 MM
- UNIFINE PROTECT PEN NEEDLE 32G X 4 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 5 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 6 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 8 MM
- UNIFINE ULTRA PEN NEEDLE 32G X 4 MM
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 1 ML
- VANISHPOINT INSULIN SYRINGE 29G X 5/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN PEN NEEDLE 29G X 12MM

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

- VERIFINE INSULIN PEN NEEDLE 31G X 5 MM
- VERIFINE INSULIN PEN NEEDLE 32G X 6 MM
- VERIFINE INSULIN SYRINGE 28G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 30G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 1 ML
- VERIFINE PLUS PEN NEEDLE 31G X 5 MM
- VERIFINE PLUS PEN NEEDLE 31G X 8 MM
- VERIFINE PLUS PEN NEEDLE 32G X 4 MM
- VP INSULIN SYRINGE 29G X 1/2" 0.3 ML
- WEBCOL ALCOHOL PREP LARGE PAD 70 %
- WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM
- ZEVRX STERILE ALCOHOL PREP PAD PAD 70 %

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | LIFETIME |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | No |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

INTERFERON FOR MS-AVONEX

Products Affected

- AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT
- AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

INTERFERON FOR MS-BETASERON

Products Affected

- BETASERON SUBCUTANEOUS KIT

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

INTERFERON FOR MS-PLEGRIDY

Products Affected

- PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

INTERFERON GAMMA-1B

Products Affected

- ACTIMMUNE

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: CHRONIC GRANULOMATOUS DISEASE (CGD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, INFECTIOUS DISEASE SPECIALIST, OR IMMUNOLOGIST. SEVERE MALIGNANT OSTEOPETROSIS (SMO): PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR HEMATOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | RENEWAL: CGD, SMO: 1) DEMONSTRATED CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) HAS NOT RECEIVED HEMATOPOIETIC CELL TRANSPLANTATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

IPILIMUMAB

Products Affected

- YERVOY

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: UNRESECT/MET MEL: 4MO, RCC/CRC/HCC: 3MO, ALL OTHERS: 12MO. INITIAL/RENEWAL: CUTAN MEL: 6MO |
| Other Criteria | RENEWAL: ADJUVANT CUTANEOUS MELANOMA: NO EVIDENCE OF DISEASE RECURRENCE (DEFINED AS THE APPEARANCE OF ONE OR MORE NEW MELANOMA LESIONS: LOCAL, REGIONAL OR DISTANT METASTASIS). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ISAVUCONAZONIUM

Products Affected

- CRESEMBA ORAL

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INVASIVE ASPERGILLOSIS, INVASIVE MUCORMYCOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST. |
| Coverage Duration | 6 MONTHS |
| Other Criteria | INVASIVE ASPERGILLOSIS: TRIAL OF OR CONTRAINDICATION TO VORICONAZOLE. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

IVACFTOR

Products Affected

- KALYDECO

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT |
| Coverage Duration | INITIAL: 12 MONTHS. RENEWAL: LIFETIME |
| Other Criteria | CF: INITIAL: 1) NOT HOMOZYGOUS FOR F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

IVOSIDENIB

Products Affected

- TIBSOVO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

IXAZOMIB

Products Affected

- NINLARO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LAMOTRIGINE

Products Affected

- SUBVENITE ORAL SUSPENSION

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | ALL INDICATIONS: CONTRAINDICATION TO OR UNABLE TO SWALLOW LAMOTRIGINE TABLETS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

LANREOTIDE

Products Affected

- LANREOTIDE ACETATE
- SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 60 MG/0.2ML, 90 MG/0.3ML

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | ACROMEGALY: INITIAL: THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST. |
| Coverage Duration | ACROMEGALY: INITIAL/RENEWAL: 12 MOS. GEP-NETS, CARCINOID SYNDROME: 12 MOS. |
| Other Criteria | ACROMEGALY: RENEWAL: 1) REDUCTION, NORMALIZATION, OR MAINTENANCE OF IGF-1 LEVELS BASED ON AGE AND GENDER, AND 2) IMPROVEMENT OR SUSTAINED REMISSION OF CLINICAL SYMPTOMS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

LAPATINIB

Products Affected

- *lapatinib ditosylate*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LAROTRECTINIB

Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | VITRAKVI ORAL SOLUTION: 1) TRIAL OF VITRAKVI CAPSULES, OR 2) UNABLE TO TAKE CAPSULE FORMULATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

LAZERTINIB

Products Affected

- LAZCLUZE ORAL TABLET 240 MG, 80 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LEDIPASVIR-SOFOSBUVIR

Products Affected

- HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG
- HARVONI ORAL TABLET
- *ledipasvir-sofosbuvir*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | HCV RNA LEVEL WITHIN PAST 6 MONTHS. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. |
| Other Criteria | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, AND 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, TIPRANAVIR/RITONAVIR, SOFOSBUVIR (AS A SINGLE AGENT), EPCLUSA, ZEPATIER, MAVYRET, OR VOSEVI. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

LENALIDOMIDE

Products Affected

- *lenalidomide*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LENVATINIB

Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LETERMIVIR

Products Affected

- PREVYMIS ORAL TABLET

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | HSCT: NOT AT RISK FOR LATE CMV: 4 MOS, AT RISK FOR LATE CMV: 7 MOS. KIDNEY TRANSPLANT: 7 MOS. |
| Other Criteria | HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 28 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 100 DAYS POST TRANSPLANT IF NOT AT RISK FOR LATE CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE, OR BEYOND 200 DAYS POST TRANSPLANT IF AT RISK FOR LATE CMV INFECTION AND DISEASE. KIDNEY TRANSPLANT: 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 7 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 200 DAYS POST TRANSPLANT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

LEUPROLIDE

Products Affected

- *leuprolide acetate injection*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | PROSTATE CANCER: 12 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LEUPROLIDE DEPOT

Products Affected

- LEUPROLIDE ACETATE (3 MONTH)
- LUTRATE DEPOT

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LEUPROLIDE MESYLATE

Products Affected

- CAMCEVI

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LEUPROLIDE-ELIGARD

Products Affected

- ELIGARD

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LEUPROLIDE-LUPRON DEPOT

Products Affected

- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST. |
| Coverage Duration | PROSTATE CA: 12 MOS. UTERINE FIBROIDS: 3 MOS. ENDOMETRIOSIS: INITIAL/RENEWAL: 6 MOS. |
| Other Criteria | INITIAL: ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. RENEWAL: ENDOMETRIOSIS: 1) IMPROVEMENT OF PAIN RELATED TO ENDOMETRIOSIS WHILE ON THERAPY, 2) RECEIVING CONCOMITANT ADD-BACK THERAPY (I.E., COMBINATION ESTROGEN-PROGESTIN OR PROGESTIN-ONLY CONTRACEPTIVE PREPARATION), 3) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 4) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

LEUPROLIDE-LUPRON DEPOT-PED

Products Affected

- LUPRON DEPOT-PED (3-MONTH)
- LUPRON DEPOT-PED (6-MONTH)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | CENTRAL PRECOCIOUS PUBERTY (CPP): INITIAL: FEMALES: ELEVATED LEVEL OF LUTEINIZING HORMONE (LH) LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. MALES: ELEVATED LEVEL OF LH LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. |
| Age Restrictions | |
| Prescriber Restrictions | CPP: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | CPP: INITIAL: FEMALES: 1) YOUNGER THAN 8 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR BREAST DEVELOPMENT AND PUBIC HAIR GROWTH. MALES: 1) YOUNGER THAN 9 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR GENITAL DEVELOPMENT AND PUBIC HAIR GROWTH. RENEWAL: 1) TANNER STAGING AT INITIAL DIAGNOSIS HAS STABILIZED OR REGRESSED DURING THREE SEPARATE MEDICAL VISITS IN THE PREVIOUS YEAR, AND 2) HAS NOT REACHED ACTUAL AGE WHICH CORRESPONDS TO CURRENT PUBERTAL AGE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | No |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

L-GLUTAMINE

Products Affected

- *l-glutamine oral packet*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | SICKLE CELL DISEASE(SCD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST |
| Coverage Duration | INITIAL: 12 MONTHS. RENEWAL: LIFETIME. |
| Other Criteria | SCD: INITIAL: AGES 18 YEARS OR OLDER: 1) AT LEAST 2 SICKLE CELL CRISES IN THE PAST YEAR, 2) SICKLE-CELL ASSOCIATED SYMPTOMS WHICH ARE INTERFERING WITH ACTIVITIES OF DAILY LIVING, OR 3) HISTORY OF OR HAS RECURRENT ACUTE CHEST SYNDROME. AGES 5 TO 17 YEARS: APPROVED WITHOUT ADDITIONAL CRITERIA. RENEWAL: MAINTAINED OR EXPERIENCED A REDUCTION IN ACUTE COMPLICATIONS OF SCD. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

LIDOCAINE OINTMENT

Products Affected

- *lidocaine external ointment 5 %*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

LIDOCAINE PRILOCAINE

Products Affected

- *lidocaine-prilocaine external cream*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

LINVOSELTAMAB-GCPT

Products Affected

- LYNOZYFIC INTRAVENOUS SOLUTION 200 MG/10ML, 5 MG/2.5ML

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LONCASTUXIMAB TESIRINE-LPYL

Products Affected

- ZYNLONTA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LORLATINIB

Products Affected

- LORBRENA ORAL TABLET 100 MG, 25 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

LOTILANER

Products Affected

- XDEMVY

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | DEMODEX BLEPHARITIS: 18 YEARS OF AGE OR OLDER |
| Prescriber Restrictions | |
| Coverage Duration | 6 WEEKS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

LUMACFTOR-IVACFTOR

Products Affected

- ORKAMBI ORAL TABLET

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CF EXPERT. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: LIFETIME. |
| Other Criteria | CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

MACITENTAN

Products Affected

- OPSUMIT

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

MARGETUXIMAB-CMKB

Products Affected

- MARGENZA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

MARIBAVIR

Products Affected

- LIVTENCITY

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

MAVACAMTEN

Products Affected

- CAMZYOS

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY(HCM): INITIAL: LEFT VENTRICULAR OUTFLOW TRACK (LVOT) GRADIENT OF 50 MMHG OR HIGHER |
| Age Restrictions | |
| Prescriber Restrictions | OBSTRUCTIVE HCM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | OBSTRUCTIVE HCM: INITIAL: TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO A BETA-BLOCKER OR A NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER. RENEWAL: CONTINUED CLINICAL BENEFIT (E.G., REDUCTION OF SYMPTOMS, NYHA CLASSIFICATION IMPROVEMENT). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

MECASERMIN

Products Affected

- INCRELEX

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | GROWTH FAILURE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR NEPHROLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | GROWTH FAILURE: INITIAL: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF WRIST AND HAND. INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER GROWTH HORMONE MEDICATION. RENEWAL: IMPROVEMENT WHILE ON THERAPY (INCREASE IN HEIGHT OR INCREASE IN HEIGHT VELOCITY). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

MECHLORETHAMINE

Products Affected

- VALCHLOR

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

MEPOLIZUMAB

Products Affected

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY OR ALLERGY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOSINOPHILIC COPD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. |
| Coverage Duration | INITIAL: CRSWNP: 6 MO. OTHERS: 12 MO. RENEWAL: CRSWNP, ASTHMA, COPD, EGPA, HES: 12 MO. |
| Other Criteria | INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

| PA Criteria | Criteria Details |
|--------------------|---|
| | <p>EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 3) INADEQUATELY CONTROLLED DISEASE. EOSINOPHILIC COPD: USED IN COMBINATION WITH A LAMA/LABA/ICS. RENEWAL: ASTHMA: 1) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): 1) REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS, OR (C) INCREASE IN FEV1 OF AT LEAST 5 PERCENT FROM PRETREATMENT BASELINE.</p> |
| Indications | All FDA-approved Indications. |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

METYROSINE

Products Affected

- *metirosine*

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | PHEOCHROMOCYTOMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, ENDOCRINE SURGEON, OR HEMATOLOGIST-ONCOLOGIST. |
| Coverage Duration | PREOPERATIVE PREPARATION FOR SURGERY: 30 DAYS. MALIGNANT PHEOCHROMOCYTOMA: INITIAL/RENEWAL:12 MOS. |
| Other Criteria | PHEOCHROMOCYTOMA: INITIAL: HAS NON-METASTATIC PHEOCHROMOCYTOMA. PREOPERATIVE PREPARATION FOR SURGERY: USE IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR BLOCKER. RENEWAL: MALIGNANT PHEOCHROMOCYTOMA: STABLE OR CLINICAL IMPROVEMENT WHILE ON THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

MIDOSTAURIN

Products Affected

- RYDAPT

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | ACUTE MYELOID LEUKEMIA: 6 MONTHS. ADVANCED SYSTEMIC MASTOCYTOSIS: 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

MIFEPRISTONE

Products Affected

- *mifepristone oral tablet 300 mg*

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | CUSHINGS SYNDROME (CS): INITIAL: DIAGNOSIS CONFIRMED BY: 1) 24-HR URINE FREE CORTISOL (AT LEAST 2 TESTS TO CONFIRM), 2) OVERNIGHT 1MG DEXAMETHASONE TEST, OR 3) LATE NIGHT SALIVARY CORTISOL (AT LEAST 2 TESTS TO CONFIRM). |
| Age Restrictions | |
| Prescriber Restrictions | CS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | CS: INITIAL: HYPERCORTISOLISM IS NOT A RESULT OF CHRONIC GLUCOCORTICIDS. RENEWAL: 1) CONTINUES TO HAVE IMPROVEMENT OF GLUCOSE TOLERANCE OR STABLE GLUCOSE TOLERANCE (E.G., REDUCED A1C, IMPROVED FASTING GLUCOSE), 2) CONTINUES TO HAVE TOLERABILITY TO THERAPY, AND 3) CONTINUES TO NOT BE A CANDIDATE FOR SURGICAL TREATMENT OR HAS FAILED SURGERY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

MILTEFOSINE

Products Affected

- IMPAVIDO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

MIRDAMETINIB

Products Affected

- GOMEKLI ORAL CAPSULE 1 MG, 2 MG
- GOMEKLI ORAL TABLET SOLUBLE MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

MIRVETUXIMAB SORAVTANSINE-GYNX

Products Affected

- ELAHERE

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: AN OPHTHALMIC EXAM, INCLUDING VISUAL ACUITY AND SLIT LAMP EXAM, WILL BE COMPLETED PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

MOMELOTINIB

Products Affected

- OJAARA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

MOSUNETUZUMAB-AXGB

Products Affected

- LUNSUMIO
- LUNSUMIO VELO

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: INITIAL: 6 MONTHS. RENEWAL: 7 MONTHS. |
| Other Criteria | RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: RENEWAL: 1) HAS ACHIEVED A PARTIAL RESPONSE TO TREATMENT, AND 2) HAS NOT PREVIOUSLY RECEIVED MORE THAN 17 CYCLES OF TREATMENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

NARCOLEPSY AGENTS

Products Affected

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

NAXITAMAB-GQGK

Products Affected

- DANYELZA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

NERANDOMILAST

Products Affected

- JASCAYD

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: IDIOPATHIC PULMONARY FIBROSIS (IPF): A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT. PROGRESSIVE PULMONARY FIBROSIS (PPF): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) INTERSTITIAL LUNG DISEASE WITH A PROGRESSIVE PHENOTYPE (PF-ILD). |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: IPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. PPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: IPF: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, CANCER), AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: OFEV, PIRFENIDONE. PPF: 1) LUNG FUNCTION AND RESPIRATORY SYMPTOMS OR CHEST IMAGING HAVE WORSENERD/PROGRESSEDD DESPITE TREATMENT WITH MEDICATIONS USED IN CLINICAL PRACTICE FOR ILD (NOT ATTRIBUTABLE TO COMORBIDITIES SUCH AS INFECTION, HEART FAILURE), AND 2) TRIAL OF OR CONTRAINDICATION |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| | TO THE PREFERRED AGENT: OFEV (NINTEDANIB). RENEWAL: IPF, PPF: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

NERATINIB

Products Affected

- NERLYNX

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | EARLY-STAGE (STAGE I-III) BREAST CANCER: MEDICATION IS BEING REQUESTED WITHIN 2 YEARS OF COMPLETING THE LAST TRASTUZUMAB DOSE. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

NILOTINIB - TASIGNA

Products Affected

- *nilotinib hcl oral capsule 150 mg, 200 mg, 50 mg*
- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND MEDICATION IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

NILOTINIB-DANZITEN

Products Affected

- DANZITEN

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): 1) PERFORMED MUTATIONAL ANALYSIS PRIOR TO INITIATION OF THERAPY, AND 2) THERAPY IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

NINTEDANIB

Products Affected

- *nintedanib esylate*
- OFEV

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: IDIOPATHIC PULMONARY FIBROSIS (IPF): A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 40% OF PREDICTED VALUE. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE WITH A PROGRESSIVE PHENOTYPE (PF-ILD): AT LEAST 10% FIBROSIS ON A CHEST HRCT. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: IPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. SSC-ILD, PF-ILD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST. |
| Coverage Duration | INITIAL: SSC-ILD: 6 MOS. IPF, PF-ILD: 12 MOS. RENEWAL (ALL INDICATIONS): 12 MOS. |
| Other Criteria | INITIAL: IPF: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ESBRIET (PIRFENIDONE). SSC-ILD: DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., HEART FAILURE/FLUID OVERLOAD, DRUG-INDUCED LUNG TOXICITY, RECURRENT ASPIRATION). PF-ILD: LUNG FUNCTION AND RESPIRATORY SYMPTOMS OR CHEST IMAGING HAVE WORSENEDED/PROGRESSED DESPITE TREATMENT WITH |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | MEDICATIONS USED IN CLINICAL PRACTICE FOR ILD (NOT ATTRIBUTABLE TO COMORBIDITIES SUCH AS INFECTION, HEART FAILURE). RENEWAL: IPF, SSC-ILD, PF-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

NIRAPARIB

Products Affected

- ZEJULA ORAL CAPSULE
- ZEJULA ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: 1) ZEJULA WILL BE USED AS MONOTHERAPY, AND 2) ZEJULA IS STARTED NO LATER THAN 8 WEEKS AFTER THE MOST RECENT PLATINUM-CONTAINING REGIMEN. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

NIRAPARIB-ABIRATERONE

Products Affected

- AKEEGA

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

NIROGACESTAT

Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

NITISINONE

Products Affected

- nitisinone*
- ORFADIN ORAL SUSPENSION

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | HEREDITARY TYROSINEMIA TYPE 1 (HT-1): INITIAL: DIAGNOSIS CONFIRMED BY ELEVATED URINARY OR PLASMA SUCCINYLACETONE LEVELS OR A MUTATION IN THE FUMARYLACETOACETATE HYDROLASE GENE. RENEWAL: URINARY OR PLASMA SUCCINYLACETONE LEVELS HAVE DECREASED FROM BASELINE WHILE ON TREATMENT WITH NITISINONE. |
| Age Restrictions | |
| Prescriber Restrictions | HT-1: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PRESCRIBER SPECIALIZING IN INHERITED METABOLIC DISEASES. |
| Coverage Duration | INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. |
| Other Criteria | HT-1: INITIAL: ORFADIN SUSPENSION: TRIAL OF OR CONTRAINDICATION TO PREFERRED NITISINONE TABLETS OR CAPSULES. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

NIVOLUMAB

Products Affected

- OPDIVO

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

NIVOLUMAB-HYALURONIDASE-NVHY

Products Affected

- OPDIVO QVANTIG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

NIVOLUMAB-RELATLIMAB-RMBW

Products Affected

- OPDUALAG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

NOGAPENDEKIN ALFA

Products Affected

- ANKTIVA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 40 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

OFATUMUMAB SQ

Products Affected

- KESIMPTA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

OLAPARIB

Products Affected

- LYNPARZA ORAL TABLET

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER: MEDICATION WILL BE USED AS MONOTHERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

OLUTASIDENIB

Products Affected

- REZLIDHIA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

OMACETAXINE

Products Affected

- SYNRIBO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

OMALIZUMAB

Products Affected

- XOLAIR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: ASTHMA: POSITIVE SKIN PRICK OR BLOOD TEST (E.G., ELISA, FEIA) TO A PERENNIAL AEROALLERGEN AND A BASELINE IGE SERUM LEVEL OF AT LEAST 30 IU/ML. FOOD ALLERGY: 1) IGE SERUM LEVEL OF AT LEAST 30 IU/ML, AND 2) POSITIVE SKIN PRICK TEST TO AT LEAST ONE FOOD, OR POSITIVE MEDICALLY MONITORED FOOD CHALLENGE TO AT LEAST ONE FOOD. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL/RENEWAL: CHRONIC SPONTANEOUS URTICARIA (CSU): PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST. INITIAL: CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. FOOD ALLERGY: PRESCRIBED BY OR IN CONSULTATION WITH ALLERGIST OR IMMUNOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: ASTHMA 12 MO/12 MO, CSU 6 MO/12 MO, CRSWNP 6 MO/12 MO, FOOD ALLERGY 12 MO/24 MO |
| Other Criteria | INITIAL: CSU: 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE, 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA ON MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS, AND 3) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: DUPIXENT. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

| PA Criteria | Criteria Details |
|-----------------------|---|
| | <p>AGENTS: NUCALA, DUPIXENT, 3) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 4) INADEQUATELY CONTROLLED DISEASE. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA. FOOD ALLERGY: CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION .</p> <p>INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE. CRSWNP: CLINICAL BENEFIT COMPARED TO BASELINE. ASTHMA: 1) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. FOOD ALLERGY: 1) PERSISTENT IGE-MEDIATED FOOD ALLERGY, AND 2) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

OSIMERTINIB

Products Affected

- TAGRISSO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

OXANDROLONE

Products Affected

- oxandrolone oral*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 MONTHS |
| Other Criteria | PROTEIN CATABOLISM, BONE PAIN: 1) MONITORED FOR PELIOSIS HEPATIS, LIVER CELL TUMORS, AND BLOOD LIPID CHANGES, 2) DOES NOT HAVE KNOWN OR SUSPECTED: CARCINOMA OF THE PROSTATE OR BREAST IN MALE PATIENTS, CARCINOMA OF THE BREAST IN FEMALES WITH HYPERCALCEMIA, NEPHROSIS (THE NEPHROTIC PHASE OF NEPHRITIS), OR HYPERCALCEMIA, AND 3) DOES NOT HAVE SEVERE HEPATIC DYSFUNCTION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

PACRITINIB

Products Affected

- VONJO

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

PALBOCICLIB

Products Affected

- IBRANCE

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

PASIREOTIDE DIASPARTATE

Products Affected

- SIGNIFOR

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | CUSHINGS DISEASE (CD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | CD: RENEWAL: 1) CONTINUED IMPROVEMENT OF CUSHINGS DISEASE, AND 2) MAINTAINED TOLERABILITY TO SIGNIFOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

PAZOPANIB

Products Affected

- *pazopanib hcl oral tablet 200 mg, 400 mg*

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | ADVANCED SOFT TISSUE SARCOMA (STS): NOT USED FOR ADIPOCYTIC STS OR GASTROINTESTINAL STROMAL TUMORS (GIST) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

PEGFILGRASTIM - APGF

Products Affected

- NYVEPRIA

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

PEGFILGRASTIM - CBQV

Products Affected

- UDENYCA ONBODY

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | NON MYELOID MALIGNANCY: UDENYCA: TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT NYVEPRIA. UDENYCA ONBODY: 1) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT NYVEPRIA, OR 2) BARRIER TO ACCESS (E.G., TRAVEL BARRIERS, UNABLE TO RETURN TO CLINIC FOR INJECTIONS). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

PEGINTERFERON ALFA-2A

Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | HEPATITIS B: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, OR PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G., HEPATOLOGIST). |
| Coverage Duration | HEP B/HEP C: 48 WEEKS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

PEGVISOMANT

Products Affected

- SOMAVERT

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

PEMBROLIZUMAB

Products Affected

- KEYTRUDA INTRAVENOUS SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

PEMBROLIZUMAB-BERAHYALURONIDASE ALFA-PMPH

Products Affected

- KEYTRUDA QLEX

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

PEMIGATINIB

Products Affected

- PEMAZYRE

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | CHOLANGIOCARCINOMA, MYELOID/LYMPHOID NEOPLASMS: COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), WILL BE COMPLETED PRIOR TO INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

PENICILLAMINE TABLET

Products Affected

- *penicillamine oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: CYSTINURIA: HAS NEPHROLITHIASIS AND ONE OF THE FOLLOWING: 1) STONE ANALYSIS SHOWING PRESENCE OF CYSTINE, 2) PRESENCE OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, OR 3) FAMILY HISTORY OF CYSTINURIA AND POSITIVE CYANIDE-NITROPRUSSIDE SCREENING. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: WILSONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. CYSTINURIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. |
| Coverage Duration | INITIAL: 12 MONTHS, RENEWAL: LIFETIME. |
| Other Criteria | INITIAL: WILSONS DISEASE: 1) LEIPZIG SCORE OF 4 OR GREATER. RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) EXPERIENCED OR MAINTAINED IMPROVEMENT IN TENDER JOINT COUNT OR SWOLLEN JOINT COUNT COMPARED TO BASELINE. WILSONS DISEASE, CYSTINURIA: CONTINUES TO BENEFIT FROM THE MEDICATION. |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

PEXIDARTINIB

Products Affected

- TURALIO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

PIMAVANSERIN

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | PSYCHOSIS IN PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OR OLDER |
| Prescriber Restrictions | PSYCHOSIS IN PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (E.G., PSYCHIATRIST). |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | PSYCHOSIS IN PD: RENEWAL: IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

PIRFENIDONE

Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | IDIOPATHIC PULMONARY FIBROSIS (IPF): INITIAL: A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT. |
| Age Restrictions | |
| Prescriber Restrictions | IPF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | IPF: INITIAL: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, OR CANCER). RENEWAL: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | No |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

PIRTOBRUTINIB

Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

POMALIDOMIDE

Products Affected

- *pomalidomide*
- POMALYST

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

PONATINIB

Products Affected

- ICLUSIG

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | CHRONIC MYELOID LEUKEMIA (CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND ICLUSIG IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

POSACONAZOLE TABLET

Products Affected

- *posaconazole oral tablet delayed release*

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE, PROPHYLAXIS: 6 MONTHS. TREATMENT: 12 WEEKS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

PRALSETINIB

Products Affected

- GAVRETO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

PYRIMETHAMINE

Products Affected

- *pyrimethamine oral*

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | TOXOPLASMOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST. |
| Coverage Duration | TOXOPLASMOSIS: INITIAL: 8 WEEKS, RENEWAL: 6 MOS. |
| Other Criteria | TOXOPLASMOSIS: RENEWAL: ONE OF THE FOLLOWING: (1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING), OR (2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENTLY TAKING AN ANTI-RETROVIRAL THERAPY IF HIV POSITIVE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

QUININE

Products Affected

- *quinine sulfate oral*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

QUIZARTINIB

Products Affected

- VANFLYTA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

REGORAFENIB

Products Affected

- STIVARGA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

RELUGOLIX

Products Affected

- ORGOVYX

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

REPOTRECTINIB

Products Affected

- AUGTYRO ORAL CAPSULE 160 MG, 40 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

RESMETIROM

Products Affected

- REZDIFFRA

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | NONALCOHOLIC STEATOHEPATITIS (NASH): INITIAL: DIAGNOSIS CONFIRMED BY BIOPSY OR NONINVASIVE TESTING, OBTAINED IN THE PAST 12 MONTHS, DEMONSTRATING: 1) LIVER FIBROSIS STAGE 2 OR 3, OR 2) NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACTIVITY SCORE OF 4 OR MORE. |
| Age Restrictions | |
| Prescriber Restrictions | NASH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST, GASTROENTEROLOGIST, OR ENDOCRINOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | NASH: RENEWAL: CONTINUES TO HAVE NONCIRRHOTIC NASH WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

RETIFANLIMAB-DLWR

Products Affected

- ZYNYZ

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

REVUMENIB

Products Affected

- REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

RIBOCICLIB

Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

RIBOCICLIB-LETROZOLE

Products Affected

- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

RIFAXIMIN

Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | TRAVELERS DIARRHEA, HEPATIC ENCEPHALOPATHY (HE): 12 MOS. IBS-D: 8 WKS. |
| Other Criteria | HE: TRIAL OF OR CONTRAINDICATION TO LACTULOSE OR CONCURRENT LACTULOSE THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

RILONACEPT

Products Affected

- ARCALYST

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES.</p> <p>DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS.</p> <p>RECURRENT PERICARDITIS (RP): TWO OF THE FOLLOWING: CHEST PAIN CONSISTENT WITH PERICARDITIS, PERICARDIAL FRICTION RUB, ECG SHOWING DIFFUSE ST-SEGMENT ELEVATION OR PR-SEGMENT DEPRESSION, NEW OR WORSENING PERICARDIAL EFFUSION.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CAPS, DIRA: LIFETIME. RP: 12 MONTHS. |
| Other Criteria | CAPS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | INHIBITOR, PDE-4 INHIBITOR) FOR CAPS. DIRA: 1) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR DIRA, AND 2) TRIAL OF THE PREFERRED AGENT: KINERET. RP: 1) HAD AN EPISODE OF ACUTE PERICARDITIS, 2) SYMPTOM-FREE FOR 4 TO 6 WEEKS, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR RP. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

RILUZOLE

Products Affected

- TIGLUTIK

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | 18 YEARS OR OLDER |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | AMYOTROPHIC LATERAL SCLEROSIS (ALS): (1) TRIAL OF RILUZOLE TABLETS, AND (2) PATIENT IS UNABLE TO TAKE TABLET FORMULATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

RIMEGEPANT

Products Affected

- NURTEC

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | ACUTE MIGRAINE TREATMENT: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN). INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR 2) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS. EPISODIC MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

RIOCIQUAT

Products Affected

- ADEMPAS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PULMONARY ARTERIAL HYPERTENSION (PAH): DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) (WHO GROUP 4): WHO FUNCTIONAL CLASS II-IV SYMPTOMS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PAH, CTEPH: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PAH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PHOSPHODIESTERASE (PDE) INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. CTEPH: 1) NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS, AND 2) NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH OR HAS PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. RENEWAL: PAH, CTEPH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

RIPRETINIB

Products Affected

- QINLOCK

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

RISANKIZUMAB-RZAA

Products Affected

- SKYRIZI
- SKYRIZI PEN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PLAQUE PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSO, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

RITUXIMAB AND HYALURONIDASE HUMAN-SQ

Products Affected

- RITUXAN HYCELA

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | FOLLICULAR LYMPHOMA (FL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 1) HAS RECEIVED OR WILL RECEIVE AT LEAST ONE FULL DOSE OF A RITUXIMAB PRODUCT BY INTRAVENOUS INFUSION PRIOR TO INITIATION OF RITUXIMAB AND HYALURONIDASE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

RITUXIMAB-ABBS

Products Affected

- TRUXIMA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST. |
| Coverage Duration | RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA, PV: 12 MO. CLL: 6 MO. |
| Other Criteria | INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: RA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

ROPEGINTERFERON ALFA-2B-NJFT

Products Affected

- BESREMI

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

RUCAPARIB

Products Affected

- RUBRACA

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

RUXOLITINIB

Products Affected

- JAKAFI

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | MYELOFIBROSIS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. POLYCYTHEMIA VERA, GVHD: 12 MONTHS. |
| Other Criteria | INITIAL: CHRONIC GRAFT VS HOST DISEASE (CGVHD): NO CONCURRENT USE WITH REZUROCK, NIKTIMVO, OR IMBRUVICA. RENEWAL: MYELOFIBROSIS: CONTINUES TO BENEFIT FROM THE MEDICATION. CGVHD: NO CONCURRENT USE WITH REZUROCK, NIKTIMVO, OR IMBRUVICA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

SAPROPTERIN

Products Affected

- *javygtor oral tablet*
- *sapropterin dihydrochloride oral tablet*

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 2 MONTHS, RENEWAL 12 MONTHS. |
| Other Criteria | HYPERPHENYLALANINEMIA (HPA): INITIAL: NO CONCURRENT USE WITH PALYNZIQ. RENEWAL: 1) CONTINUES TO BENEFIT FROM TREATMENT, AND 2) NO CONCURRENT USE WITH PALYNZIQ. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

SECUKINUMAB SQ

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI). |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, ENTHESITIS-RELATED ARTHRITIS (ERA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. |
| Coverage Duration | INITIAL: HS: 12 MONTHS, ALL OTHER INDICATIONS: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. AS, NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. ERA: |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| | TRIAL OF OR CONTRAINDICATION TO ONE NSAID, SULFASALAZINE, OR METHOTREXATE. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

SELEXIPAG

Products Affected

- UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- UPTRAVI TITRATION

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | PAH: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING AGENTS: 1) FORMULARY VERSION OF AN ORAL ENDOTHELIN RECEPTOR ANTAGONIST, 2) FORMULARY VERSION OF AN ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, 3) FORMULARY VERSION OF AN ORAL CGMP STIMULATOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

SELINEXOR

Products Affected

- XPOVIO (100 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 50
MG
- XPOVIO (40 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 10
MG, 40 MG
- XPOVIO (40 MG TWICE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG
- XPOVIO (60 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 60
MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG, 80 MG
- XPOVIO (80 MG TWICE WEEKLY)

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

SELPERCATINIB

Products Affected

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

SELUMETINIB

Products Affected

- KOSELUGO ORAL CAPSULE 10 MG, 25 MG
- KOSELUGO ORAL CAPSULE SPRINKLE 5 MG, 7.5 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

SEVABERTINIB

Products Affected

- HYRNUO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

SILDENAFIL TABLET

Products Affected

- sildenafil citrate oral tablet 20 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: AGES 18 YEARS OR OLDER: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. AGES 1 TO 17 YEARS: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PAP GREATER THAN 20 MMHG, 2) PCWP OF 15 MMHG OR LESS, AND 3) PVR OF 3 WOOD UNITS OR GREATER. |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | No |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

SIPONIMOD

Products Affected

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER PACK

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

SIROLIMUS PROTEIN-BOUND

Products Affected

- FYARRO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

SODIUM OXYBATE-XYREM

Products Affected

- sodium oxybate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: CATAPLEXY IN NARCOLEPSY, EXCESSIVE DAYTIME SLEEPINESS (EDS) IN NARCOLEPSY: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR SPECIALIST IN SLEEP MEDICINE |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL: EDS IN NARCOLEPSY: 1) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT, AND 2) AGES 18 YEARS OR OLDER: TRIAL, FAILURE OF, OR CONTRAINDICATION TO A FORMULARY VERSION OF MODAFINIL, ARMODAFINIL, OR SUNOSI AND ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY. CATAPLEXY IN NARCOLEPSY: NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT. RENEWAL: CATAPLEXY IN NARCOLEPSY, EDS IN NARCOLEPSY: 1) SUSTAINED IMPROVEMENT OF SYMPTOMS COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

SOFOSBUVIR/VELPATASVIR

Products Affected

- EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG
- EPCLUSA ORAL TABLET
- *sofosbuvir-velpatasvir*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | HCV RNA LEVEL WITHIN PAST 6 MONTHS. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. |
| Other Criteria | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANA VIR/RITONAVIR, TOPOTECAN, SOVALDI (AS A SINGLE AGENT), HARVONI, ZEPATIER, MAVYRET, OR VOSEVI, AND 3) PATIENTS WITH DECOMPENSATED CIRRHOSIS REQUIRE CONCURRENT RIBAVIRIN UNLESS RIBAVIRIN INELIGIBLE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | No |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

Products Affected

- VOSEVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | HCV RNA LEVEL WITHIN PAST 6 MONTHS |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE. |
| Other Criteria | 1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR, TIPRANAVIR/RITONAVIR, SOVALDI (AS A SINGLE AGENT), EPCLUSA, HARVONI, ZEPATIER, OR MAVYRET, AND 3) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | No |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

SOMATROPIN - NORDITROPIN

Products Affected

- NORDITROPIN FLEXPRO
SUBCUTANEOUS SOLUTION PEN-
INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES. |
| Required Medical Information | INITIAL: PEDIATRIC GROWTH HORMONE DEFICIENCY (GHD), IDIOPATHIC SHORT STATURE (ISS), SMALL FOR GESTATIONAL AGE (SGA), NOONAN SYNDROME: HEIGHT AT LEAST 2 STANDARD DEVIATIONS BELOW THE MEAN HEIGHT FOR CHILDREN OF THE SAME AGE AND GENDER. TURNER SYNDROME (TS): CONFIRMED BY CHROMOSOMAL ANALYSIS (KARYOTYPING). PRADER WILLI SYNDROME (PWS): CONFIRMED GENETIC DIAGNOSIS OF PWS. ADULT GHD: 1) HAS A CONGENITAL, GENETIC, OR ORGANIC DISEASE (E.G., CRANIOPHARYNGIOMA, PITUITARY HYPOPLASIA, ECTOPIC POSTERIOR PITUITARY, PREVIOUS CRANIAL IRRADIATION), OR 2) GHD CONFIRMED BY ONE OF THE FOLLOWING GROWTH HORMONE (GH) STIMULATION TESTS: (A) INSULIN TOLERANCE TEST (PEAK GH OF 5 NG/ML OR LESS), (B) GLUCAGON-STIMULATION TEST (ONE OF THE FOLLOWING: (I) PEAK RESPONSE OF 3 NG/ML OR LESS AND BMI LESS THAN 25 KG/M2, (II) PEAK RESPONSE OF 3 NG/ML OR LESS AND BMI IS BETWEEN 25 - 30 KG/M2 WITH A PRE-TEST PROBABILITY, (III) PEAK RESPONSE OF 1 NG/ML OR LESS AND BMI IS BETWEEN 25 - 30 KG/M2 WITH LOW TEST PROBABILITY, OR (IV) PEAK RESPONSE OF 1 NG/ML OR LESS AND BMI IS GREATER THAN 30 KG/M2), OR (C) MACIMORELIN TEST (PEAK GH OF 2.8 NG/ML OR LESS). |
| Age Restrictions | SGA: 2 YEARS OF AGE OR OLDER. |
| Prescriber Restrictions | INITIAL/RENEWAL: ALL INDICATIONS: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST. |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | <p>INITIAL: PEDIATRIC GHD, ISS, SGA, TS, NOONAN SYNDROME: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. INITIAL/RENEWAL: ADULT GHD, PEDIATRIC GHD, SGA, TS, PWS, NOONAN SYNDROME: NO CONCURRENT USE WITH INCRELEX. RENEWAL: ISS: 1) IMPROVEMENT WHILE ON THERAPY (INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. PEDIATRIC GHD, SGA, TS, NOONAN SYNDROME: 1) IMPROVEMENT WHILE ON THERAPY (INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND OR HAS NOT COMPLETED PREPUBERTAL GROWTH. PWS: IMPROVEMENT IN BODY COMPOSITION.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

SOMATROPIN - SEROSTIM

Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES |
| Required Medical Information | INITIAL: HIV/WASTING: ONE OF THE FOLLOWING FOR WEIGHT LOSS: 1) 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS OR 5% WEIGHT LOSS OVER 6 MONTHS, 2) 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, 3) BCM LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, 4) BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND BMI LESS THAN 27 KG PER METER SQUARED, OR 5) BMI LESS THAN 20 KG PER METER SQUARED. |
| Age Restrictions | |
| Prescriber Restrictions | HIV/WASTING: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST, OR INFECTIOUS DISEASE SPECIALIST. |
| Coverage Duration | INITIAL/RENEWAL: 9 MONTHS. |
| Other Criteria | HIV/WASTING: RENEWAL: 1) CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | No |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

SONIDEGIB

Products Affected

- ODOMZO

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC): BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

SORAFENIB

Products Affected

- *sorafenib tosylate*

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

SOTATERCEPT-CSRK

Products Affected

- WINREVAIR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | PAH: INITIAL: 1) ON BACKGROUND PAH THERAPY (FOR AT LEAST 3 MONTHS) WITH AT LEAST TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: A) ORAL ENDOTHELIN RECEPTOR ANTAGONIST, B) ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, C) ORAL CGMP STIMULATOR, D) IV/SQ PROSTACYCLIN, OR 2) ON ONE AGENT FROM ONE OF THE ABOVE DRUG CLASSES, AND HAS A CONTRAINDICATION OR INTOLERANCE TO ALL OF THE OTHER DRUG CLASSES. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

SOTORASIB

Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

STIRIPENTOL

Products Affected

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL PACKET 250 MG, 500 MG

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | DRAVET SYNDROME: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

SUNITINIB

Products Affected

- *sunitinib malate*

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO IMATINIB. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TADALAFIL - ADCIRCA, ALYQ

Products Affected

- *alyq*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. |
| Age Restrictions | |
| Prescriber Restrictions | PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM, AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TADALAFIL-CIALIS

Products Affected

- *tadalafil oral tablet 2.5 mg, 5 mg*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | ERECTILE DYSFUNCTION WITHOUT DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH). |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | BPH: 1) TRIAL OF ONE ALPHA BLOCKER (E.G., DOXAZOSIN, TERAZOSIN, TAMSULOSIN, ALFUZOSIN), AND 2) TRIAL OF ONE 5-ALPHA-REDUCTASE INHIBITOR (E.G., FINASTERIDE, DUTASTERIDE). APPLIES TO 2.5MG AND 5MG STRENGTHS ONLY. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TAFAMIDIS

Products Affected

- VYNDAMAX

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | CARDIOMYOPATHY ASSOCIATED WITH WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM): INITIAL: 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS I, II, OR III HEART FAILURE, AND 2) DIAGNOSIS CONFIRMED BY (A) BONE SCAN (SCINTIGRAPHY) STRONGLY POSITIVE FOR MYOCARDIAL UPTAKE OF TC-99M-PYP, OR (B) BIOPSY OF TISSUE OF AFFECTED ORGAN(S) (CARDIAC AND POSSIBLY NON-CARDIAC SITES) TO CONFIRM AMYLOID PRESENCE AND CHEMICAL TYPING TO CONFIRM PRESENCE OF TRANSTHYRETIN (TTR) PROTEIN. |
| Age Restrictions | |
| Prescriber Restrictions | ATTR-CM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ATTR SPECIALIST, OR MEDICAL GENETICIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | ATTR-CM: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER ATTR-CM TTR STABILIZERS (E.G., ACORAMIDIS) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TALAZOPARIB

Products Affected

- TALZENNA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | ADVANCED OR METASTATIC BREAST CANCER: 1) HAS BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND 2) IF HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER, RECEIVED PRIOR TREATMENT WITH ENDOCRINE THERAPY OR IS CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

TALETRECTINIB

Products Affected

- IBTROZI

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TALQUETAMAB-TGVS

Products Affected

- TALVEY

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TARLATAMAB-DLLE

Products Affected

- IMDELLTRA

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TAZEMETOSTAT

Products Affected

- TAZVERIK

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TEBENTAFUSP-TEBN

Products Affected

- KIMMTRAK

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TECLISTAMAB-CQYV

Products Affected

- TECVAYLI

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

TELISOTUZUMAB VEDOTIN-TLLV

Products Affected

- EMRELIS

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TELOTRISTAT

Products Affected

- XERMELO

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | CARCINOID SYNDROME DIARRHEA: PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST OR GASTROENTEROLOGIST |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TEPOTINIB

Products Affected

- TEPMETKO

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TERIPARATIDE

Products Affected

- *teriparatide subcutaneous solution pen-injector 560 mcg/2.24ml*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 MONTHS |
| Other Criteria | OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY, UNLESS REMAINS AT OR HAS RETURNED TO HAVING A HIGH RISK FOR FRACTURE. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TESTOSTERONE

Products Affected

- *testosterone gel 1.62 % transdermal*
- *testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TESTOSTERONE CYPIONATE - DEPO

Products Affected

- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS |
| Other Criteria | MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TESTOSTERONE ENANTHATE

Products Affected

- *testosterone enanthate intramuscular solution*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL/RENEWAL: MALE DELAYED PUBERTY: 6MO, MALE HYPOGONADISM: 12 MO. OTHER INDICATIONS: 12 MO. |
| Other Criteria | INITIAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. MALE DELAYED PUBERTY: HAS NOT RECEIVED MORE THAN TWO 6-MONTH COURSES OF TESTOSTERONE REPLACEMENT THERAPY |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Prerequisite Therapy Required | No |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

TETRABENAZINE

Products Affected

- tetrabenazine*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

THALIDOMIDE

Products Affected

- THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TISLELIZUMAB-JSGR

Products Affected

- TEVIMBRA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

TISOTUMAB VEDOTIN-TFTV

Products Affected

- TIVDAK

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TIVOZANIB

Products Affected

- FOTIVDA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TOCILIZUMAB-AAZG IV

Products Affected

- TYENNE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST. |
| Coverage Duration | INITIAL: RA, PJIA, SJIA, GCA: 6 MONTHS. CRS: 1 MONTH. RENEWAL: RA, PJIA, SJIA, GCA: 12 MONTHS. |
| Other Criteria | INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. GIANT CELL ARTERITIS (GCA): 1) HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICIDS, AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: RINVOQ. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ IR, ORENCIA, RINVOQ. RENEWAL: RA, PJIA, SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | GCA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TOCILIZUMAB-AAZG SQ

Products Affected

- TYENNE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS |
| Other Criteria | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. GIANT CELL ARTERITIS (GCA): 1) HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOID, AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: RINVOQ. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PJIA, SJIA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TOFACITINIB

Products Affected

- XELJANZ
- XELJANZ XR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, PCJIA: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

TOLVAPTAN

Products Affected

- JYNARQUE ORAL TABLET
- *tolvaptan oral tablet therapy pack*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): INITIAL: CONFIRMED POLYCYSTIC KIDNEY DISEASE VIA CT, MRI, OR ULTRASOUND. |
| Age Restrictions | |
| Prescriber Restrictions | ADPKD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | ADPKD: INITIAL: DOES NOT HAVE ESRD (I.E., RECEIVING DIALYSIS). RENEWAL: HAS NOT PROGRESSED TO ESRD/DIALYSIS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TOPICAL TRETINOIN

Products Affected

- ALTRENO
- *tretinoin external gel 0.01 %, 0.025 %*
- *tretinoin external cream*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | COSMETIC INDICATIONS SUCH AS WRINKLES, PHOTOAGING, MELASMA. |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | ACNE VULGARIS: BRAND TOPICAL TRETINOIN REQUIRES TRIAL OF OR CONTRAINDICATION TO A GENERIC TOPICAL TRETINOIN PRODUCT. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TORIPALIMAB-TPZI

Products Affected

- LOQTORZI

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | NASOPHARYNGEAL CARCINOMA (NPC): FIRST LINE TREATMENT: 24 MOS, PREVIOUSLY TREATED: LIFETIME. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

TOVORAFENIB

Products Affected

- OJEMDA ORAL SUSPENSION RECONSTITUTED
- OJEMDA ORAL TABLET

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TRAMADOL

Products Affected

- *tramadol hcl oral solution*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 MONTHS |
| Other Criteria | PAIN: 1) TRIAL OF OR CONTRAINDICATION TO GENERIC TRAMADOL IMMEDIATE RELEASE TABLET OR GENERIC TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT, AND 2) UNABLE TO TAKE ORAL SOLID FORMULATIONS OF TRAMADOL OR TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT (E.G., DIFFICULTY SWALLOWING). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TRAMETINIB SOLUTION

Products Affected

- MEKINIST ORAL SOLUTION RECONSTITUTED

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | UNRESECTABLE OR METASTATIC MELANOMA, MELANOMA, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC), UNRESECTABLE OR METASTATIC SOLID TUMOR, LOW-GRADE GLIOMA (LGG): UNABLE TO SWALLOW MEKINIST TABLETS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TRAMETINIB TABLET

Products Affected

- MEKINIST ORAL TABLET 0.5 MG, 2 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TRASTUZUMAB-DKST

Products Affected

- OGIVRI

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TRASTUZUMAB-HYALURONIDASE-OYSK

Products Affected

- HERCEPTIN HYLECTA

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | ADJUVANT BREAST CANCER, METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: HERZUMA, OGIVRI, ONTRUZANT, TRAZIMERA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TRAZODONE

Products Affected

- RALDESY

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | MAJOR DEPRESSIVE DISORDER (MDD); CONTRAINDICATION TO OR UNABLE TO SWALLOW TRAZODONE TABLETS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TREMELIMUMAB-ACTL

Products Affected

- IMJUDO

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | UHCC: 30 DAYS. METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): 5 MONTHS. |
| Other Criteria | UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC): HAS NOT RECEIVED PRIOR TREATMENT WITH IMJUDO. NSCLC: HAS NOT RECEIVED A TOTAL OF 5 DOSES OF IMJUDO. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TREPROSTINIL-YUTREPIA

Products Affected

- YUTREPIA

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PULMONARY ARTERIAL HYPERTENSION (PAH), PULMONARY HYPERTENSION-INTERSTITIAL LUNG DISEASE (PH-ILD): DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PAH, PH-ILD: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST. |
| Coverage Duration | INITIAL/RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PAH: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: 1) ORAL ENDOTHELIN RECEPTOR ANTAGONIST, 2) ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, 3) ORAL CGMP STIMULATOR, 4) IV/SQ PROSTACYCLIN. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TRIENTINE CAPSULE

Products Affected

- *trientine hcl oral capsule 250 mg*

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | WILSONS DISEASE: INITIAL: LEIPZIG SCORE OF 4 OR GREATER. |
| Age Restrictions | |
| Prescriber Restrictions | WILSONS DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 12 MONTHS, RENEWAL: LIFETIME. |
| Other Criteria | WILSONS DISEASE: INITIAL: TRIAL OF OR CONTRAINDICATION TO FORMULARY VERSION OF PENICILLAMINE TABLET. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TRIFLURIDINE/TIPIRACIL

Products Affected

- LONSURF ORAL TABLET 15-6.14 MG,
20-8.19 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

TRIPTORELIN-TRELSTAR

Products Affected

- TRELSTAR MIXJECT

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS. |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

TUCATINIB

Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

UBROGEPANT

Products Affected

- UBRELVY

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | ACUTE MIGRAINE TREATMENT: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

UPADACITINIB

Products Affected

- RINVOQ
- RINVOQ LQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI). |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. AD: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST, OR IMMUNOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, AND 2) TRIAL OF OR CONTRAINDICATION TO A TOPICAL CORTICOSTEROID, TOPICAL CALCINEURIN INHIBITOR, TOPICAL PDE4 INHIBITOR, OR TOPICAL JAK INHIBITOR. AS, |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| | <p>NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID (NON-STEROIDAL ANTI-INFLAMMATORY DRUG). GIANT CELL ARTERITIS (GCA): HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOIDS.</p> <p>INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, NR-AXSPA, PJIA: CONTINUES TO BENEFIT FROM THE MEDICATION. AD: IMPROVEMENT WHILE ON THERAPY.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

USTEKINUMAB-AAUZ SQ

Products Affected

- *ustekinumab-aauz*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

USTEKINUMAB-AEKN IV

Products Affected

- SELARSDI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

USTEKINUMAB-AEKN SQ

Products Affected

- SELARSDI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

USTEKINUMAB-KFCE IV

Products Affected

- YESINTEK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

USTEKINUMAB-KFCE SQ

Products Affected

- YESINTEK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE. |
| Age Restrictions | |
| Prescriber Restrictions | INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS. |
| Other Criteria | INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------|
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
Formulary ID: 26389 Version 12
Last Updated: 06/01/2026
Effective: 06/01/2026

VALBENZAZINE

Products Affected

- INGREZZA ORAL CAPSULE
- INGREZZA ORAL CAPSULE SPRINKLE
- INGREZZA ORAL CAPSULE THERAPY PACK

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | TARDIVE DYSKINESIA (TD): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. |
| Coverage Duration | 12 MONTHS |
| Other Criteria | TD: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

VANDETANIB

Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | CURRENTLY STABLE ON CAPRELSA REQUIRES NO EXTRA CRITERIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

VANZACAFITOR-TEZACAFITOR-DEUTIVACAFITOR

Products Affected

- ALYFTREK ORAL TABLET 10-50-125 MG, 4-20-50 MG

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT. |
| Coverage Duration | INITIAL: 6 MONTHS. RENEWAL: LIFETIME. |
| Other Criteria | CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

VEMURAFENIB

Products Affected

- ZELBORAF

| PA Criteria | Criteria Details |
|-------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | MELANOMA: ZELBORAF WILL BE USED ALONE OR IN COMBINATION WITH COTELLIC |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

VENETOCLAX

Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

VERICIGUAT

Products Affected

- VERQUVO

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL/RENEWAL:12 MONTHS. |
| Other Criteria | HEART FAILURE (HF): INITIAL: 1) TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO ONE PREFERRED SGLT-2 INHIBITOR, AND 2) TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO ONE AGENT FROM ANY OF THE FOLLOWING STANDARD OF CARE CLASSES: (A) ACE INHIBITOR, ARB, OR ARNI, (B) BETA BLOCKER (BISOPROLOL, CARVEDILOL, METOPROLOL SUCCINATE), OR (C) ALDOSTERONE ANTAGONIST (SPIRONOLACTONE, EPLERENONE). INITIAL/RENEWAL: NO CONCURRENT USE WITH RIOICIGUAT OR PDE-5 INHIBITORS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

VIMSELTINIB

Products Affected

- ROMVIMZA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

VISMODEGIB

Products Affected

- ERIVEDGE

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

VONOPRAZAN

Products Affected

- VOQUEZNA

| PA Criteria | Criteria Details |
|--------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | INITIAL: H PYLORI: 30 DAYS. EE: 8 WEEKS. NERD: 4 WEEKS. RENEWAL: EE: 24 WEEKS. |
| Other Criteria | INITIAL: EROSIIVE ESOPHAGITIS (EE): TRIAL OF OR CONTRAINDICATION TO TWO PROTON PUMP INHIBITORS AT MAXIMUM DOSE FOR 8 WEEKS EACH. NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (NERD): 1) NO PREVIOUS TREATMENT FAILURE WITH VOQUEZNA IN THE LAST 12 MONTHS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE PROTON PUMP INHIBITOR AT MAXIMUM DOSE FOR 8 WEEKS. RENEWAL: EE: MAINTAINED A CLINICAL RESPONSE ON VOQUEZNA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

VORASIDENIB

Products Affected

- VORANIGO

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

VORICONAZOLE SUSPENSION

Products Affected

- *voriconazole oral suspension reconstituted*

| PA Criteria | Criteria Details |
|--------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | CANDIDA INFECTIONS: 3 MOS. CONTINUATION OF THERAPY, ALL OTHER INDICATIONS: 6 MOS. |
| Other Criteria | CANDIDA INFECTIONS: CONTRAINDICATION TO OR UNABLE TO SWALLOW FLUCONAZOLE TABLETS. ALL INDICATIONS EXCEPT ESOPHAGEAL CANDIDIASIS: UNABLE TO SWALLOW TABLETS. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ZANIDATAMAB-HRII

Products Affected

- ZIIHERA

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ZANUBRUTINIB

Products Affected

- BRUKINSA ORAL CAPSULE
- BRUKINSA ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | MANTLE CELL LYMPHOMA: INTOLERANCE TO CALQUENCE. CHRONIC LYMPHOCYTIC LEUKEMIA, SMALL LYMPHOCYTIC LYMPHOMA: INTOLERANCE TO CALQUENCE OR IMBRUVICA. WALDENSTROMS MACROGLOBULINEMIA: NO STEP REQUIRED. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | Yes |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ZENOCUTUZUMAB-ZBCO

Products Affected

- BIZENGRI (750 MG DOSE)

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ZIFTOMENIB

Products Affected

- KOMZIFTI

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ZOLBETUXIMAB-CLZB

Products Affected

- VYLOY

| PA Criteria | Criteria Details |
|-------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C

Formulary ID: 26389 Version 12

Last Updated: 06/01/2026

Effective: 06/01/2026

ZONGERTINIB

Products Affected

- HERNEXEOS

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 MONTHS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

ZURANOLONE

Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

| PA Criteria | Criteria Details |
|--------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 14 DAYS |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |
| Part B Prerequisite | No |
| Prerequisite Therapy Required | No |

H1119_PA26_C
 Formulary ID: 26389 Version 12
 Last Updated: 06/01/2026
 Effective: 06/01/2026

INDEX

A

| | | | |
|--|---------------|---------------------------------------|---------------|
| abiraterone acetate | 7 | ALCOHOL SWABS PAD..... | 167, 185, 186 |
| ABIRATERONE ACETATE | | ALCOHOL SWABS PAD 70 % ... | 167, 185, 186 |
| MICRONIZED | 8 | 186 | |
| abirtega..... | 7 | ALECENSA..... | 21 |
| ABOUTTIME PEN NEEDLE 30G X 8 MM | | ALTRENO..... | 369 |
| | 167, 185, 186 | ALUNBRIG ORAL TABLET 180 MG, 30 | |
| ABOUTTIME PEN NEEDLE 31G X 5 MM | | MG, 90 MG..... | 59 |
| | 167, 185, 186 | ALUNBRIG ORAL TABLET THERAPY | |
| ABOUTTIME PEN NEEDLE 31G X 8 MM | | PACK..... | 59 |
| | 167, 185, 186 | ALVAIZ..... | 110 |
| ABOUTTIME PEN NEEDLE 32G X 4 MM | | ALYFTREK ORAL TABLET 10-50-125 | |
| | 167, 185, 186 | MG, 4-20-50 MG..... | 399 |
| ACTIMMUNE..... | 190 | alyq..... | 340 |
| adalimumab-aaty (1 pen) auto-injector kit 40 | | ANKTIVA | 253 |
| mg/0.4ml subcutaneous..... | 14, 15 | AQ INSULIN SYRINGE 31G X 5/16... 167, | |
| adalimumab-aaty (1 pen) subcutaneous auto- | | 185, 186 | |
| injector kit 80 mg/0.8ml..... | 14, 15 | AQINJECT PEN NEEDLE 31G X 5 MM | |
| adalimumab-aaty (2 pen) | 14, 15 | | 167, 185, 186 |
| adalimumab-aaty (2 syringe) | 14, 15 | AQINJECT PEN NEEDLE 32G X 4 MM | |
| adalimumab-aaty cd/uc/hs start..... | 14, 15 | | 167, 185, 186 |
| ADEMPAS | 302, 303 | ARCALYST | 297, 298 |
| ADVOCATE INSULIN PEN NEEDLE 32G | | ARIKAYCE..... | 23 |
| X 4 MM..... | 167, 185, 186 | armodafinil..... | 237 |
| ADVOCATE INSULIN PEN NEEDLES | | ASSURE ID DUO PRO PEN NEEDLES | |
| 29G X 12.7MM..... | 167, 185, 186 | 31G X 5 MM..... | 167, 185, 186 |
| ADVOCATE INSULIN PEN NEEDLES | | ASSURE ID INSULIN SAFETY SYR 29G | |
| 31G X 5 MM..... | 167, 185, 186 | X 1/2..... | 167, 185, 186 |
| ADVOCATE INSULIN PEN NEEDLES | | ASSURE ID INSULIN SAFETY SYR 31G | |
| 31G X 8 MM..... | 167, 185, 186 | X 15/64..... | 167, 185, 186 |
| ADVOCATE INSULIN PEN NEEDLES | | ASSURE ID PRO PEN NEEDLES 30G X 5 | |
| 33G X 4 MM..... | 167, 185, 186 | MM | 167, 185, 186 |
| ADVOCATE INSULIN SYRINGE 29G X | | ATTRUBY | 10 |
| 1/2 | 167, 185, 186 | AUGTYRO ORAL CAPSULE 160 MG, 40 | |
| ADVOCATE INSULIN SYRINGE 30G X | | MG | 290 |
| 5/16 | 167, 185, 186 | AUM ALCOHOL PREP PADS PAD 70 % | |
| ADVOCATE INSULIN SYRINGE 31G X | | | 167, 185, 186 |
| 5/16 | 167, 185, 186 | AUM INSULIN SAFETY PEN NEEDLE | |
| AIMOVIG..... | 123 | 31G X 4 MM..... | 167, 185, 186 |
| AKEEGA | 247 | AUM INSULIN SAFETY PEN NEEDLE | |
| ALCOHOL PREP PAD..... | 167, 185, 186 | 31G X 5 MM..... | 167, 185, 186 |
| ALCOHOL PREP PAD 70 %. 167, 185, 186 | | AUM MINI INSULIN PEN NEEDLE 32G | |
| ALCOHOL PREP PADS PAD 70 % 167, | | X 4 MM..... | 167, 185, 186 |
| 185, 186 | | AUM MINI INSULIN PEN NEEDLE 32G | |
| | | X 5 MM..... | 167, 185, 186 |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

AUM MINI INSULIN PEN NEEDLE 32G
 X 6 MM..... 167, 185, 186
 AUM MINI INSULIN PEN NEEDLE 32G
 X 8 MM..... 167, 185, 186
 AUM MINI INSULIN PEN NEEDLE 33G
 X 4 MM..... 167, 185, 186
 AUM MINI INSULIN PEN NEEDLE 33G
 X 5 MM..... 167, 185, 186
 AUM MINI INSULIN PEN NEEDLE 33G
 X 6 MM..... 167, 185, 186
 AUM PEN NEEDLE 32G X 4 MM 167,
 185, 186
 AUM PEN NEEDLE 32G X 5 MM 167,
 185, 186
 AUM PEN NEEDLE 32G X 6 MM 167,
 185, 186
 AUM PEN NEEDLE 33G X 4 MM 168,
 185, 186
 AUM PEN NEEDLE 33G X 5 MM 168,
 185, 186
 AUM PEN NEEDLE 33G X 6 MM 168,
 185, 186
 AUM READYGARD DUO PEN NEEDLE
 32G X 4 MM..... 168, 185, 186
 AUM SAFETY PEN NEEDLE 31G X 4
 MM 168, 185, 186
 AURORA PEN NEEDLES 29G X 12MM
 168, 185, 186
 AURORA PEN NEEDLES 31G X 6 MM
 168, 185, 186
 AURORA PEN NEEDLES 31G X 8 MM
 168, 185, 186
 AUSTEDO ORAL TABLET 12 MG, 6 MG,
 9 MG 89
 AUSTEDO XR ORAL TABLET
 EXTENDED RELEASE 24 HOUR 12
 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42
 MG, 48 MG, 6 MG 89
 AUSTEDO XR PATIENT TITRATION . 89
 AVMAPKI FAKZYNJA CO-PACK..... 40
 AVONEX PEN INTRAMUSCULAR
 AUTO-INJECTOR KIT..... 187
 AVONEX PREFILLED
 INTRAMUSCULAR PREFILLED
 SYRINGE KIT..... 187
 AYVAKIT 39

B
 BALVERSA ORAL TABLET 3 MG, 4
 MG, 5 MG..... 122
 BD AUTOSHIELD DUO 30G X 5 MM 168,
 185, 186
 BD ECLIPSE SYRINGE 30G X 1/2..... 168,
 185, 186
 BD INSULIN SYR ULTRAFINE II 31G X
 5/16 168, 185, 186
 BD INSULIN SYRINGE 27.5G X 5/8.. 168,
 185, 186
 BD INSULIN SYRINGE 27G X 1/2..... 168,
 185, 186
 BD INSULIN SYRINGE 29G X 1/2..... 168,
 185, 186
 BD INSULIN SYRINGE HALF-UNIT 31G
 X 5/16..... 168, 185, 186
 BD INSULIN SYRINGE MICROFINE 27G
 X 5/8..... 168, 185, 186
 BD INSULIN SYRINGE MICROFINE 28G
 X 1/2..... 168, 185, 186
 BD INSULIN SYRINGE U-100 1 ML . 168,
 185, 186
 BD INSULIN SYRINGE ULTRAFINE 29G
 X 1/2..... 168, 185, 186
 BD INSULIN SYRINGE ULTRAFINE 30G
 X 1/2..... 168, 185, 186
 BD PEN NEEDLE MICRO ULTRAFINE
 32G X 6 MM..... 168, 185, 186
 BD PEN NEEDLE MINI U/F 31G X 5 MM
 168, 185, 186
 BD PEN NEEDLE MINI ULTRAFINE 31G
 X 5 MM..... 168, 185, 186
 BD PEN NEEDLE NANO 2ND GEN 32G
 X 4 MM..... 168, 185, 186
 BD PEN NEEDLE NANO ULTRAFINE
 32G X 4 MM..... 168, 185, 186
 BD PEN NEEDLE ORIG ULTRAFINE
 29G X 12.7MM..... 168, 185, 186
 BD PEN NEEDLE SHORT ULTRAFINE
 31G X 8 MM..... 168, 185, 186
 BD SAFETYGLIDE INSULIN SYRINGE
 29G X 1/2..... 168, 185, 186
 BD SAFETYGLIDE INSULIN SYRINGE
 30G X 5/16..... 168, 185, 186

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | | | |
|--|---------------|---|---------------|
| BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64..... | 168, 185, 186 | CAPRELSA ORAL TABLET 100 MG, 300 MG | 398 |
| BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16..... | 168, 185, 186 | CAREFINE PEN NEEDLES 29G X 12MM | 169, 185, 186 |
| BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8..... | 168, 185, 186 | CAREFINE PEN NEEDLES 30G X 8 MM | 169, 185, 186 |
| BD SWAB SINGLE USE REGULAR PAD | 168, 185, 186 | CAREFINE PEN NEEDLES 31G X 6 MM | 169, 185, 186 |
| BD SWABS SINGLE USE BUTTERFLY PAD..... | 168, 185, 186 | CAREFINE PEN NEEDLES 31G X 8 MM | 169, 185, 186 |
| BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64..... | 168, 185, 186 | CAREFINE PEN NEEDLES 32G X 4 MM | 169, 185, 186 |
| BD VEO INSULIN SYR ULTRAFINE 31G X 15/64..... | 168, 185, 186 | CAREFINE PEN NEEDLES 32G X 5 MM | 169, 185, 186 |
| BD VEO INSULIN SYRINGE U/F 31G X 15/64 | 169, 185, 186 | CAREFINE PEN NEEDLES 32G X 6 MM | 169, 185, 186 |
| BENDAMUSTINE HCL INTRAVENOUS SOLUTION..... | 49 | CAREONE INSULIN SYRINGE 30G X 1/2 | 169, 185, 186 |
| bendamustine hcl intravenous solution reconstituted..... | 49 | CAREONE INSULIN SYRINGE 31G X 5/16 | 169, 185, 186 |
| BENDEKA | 49 | CARETOUCH ALCOHOL PREP PAD 70 % | 169, 185, 186 |
| BENLYSTA SUBCUTANEOUS..... | 46 | CARETOUCH INSULIN SYRINGE 28G X 5/16 | 169, 185, 186 |
| BESREMI | 310 | CARETOUCH INSULIN SYRINGE 29G X 5/16 | 169, 185, 186 |
| betaine | 52 | CARETOUCH INSULIN SYRINGE 30G X 5/16 | 169, 185, 186 |
| BETASERON SUBCUTANEOUS KIT | 188 | CARETOUCH INSULIN SYRINGE 31G X 5/16 | 169, 185, 186 |
| bexarotene | 54 | CARETOUCH PEN NEEDLES 29G X 12MM | 169, 185, 186 |
| BIZENGRI (750 MG DOSE) | 410 | CARETOUCH PEN NEEDLES 31G X 5 MM | 169, 185, 186 |
| BORTEZOMIB INJECTION SOLUTION RECONSTITUTED 1 MG, 2.5 MG..... | 56 | CARETOUCH PEN NEEDLES 31G X 6 MM | 169, 185, 186 |
| bortezomib injection solution reconstituted 3.5 mg | 56 | CARETOUCH PEN NEEDLES 31G X 8 MM | 169, 185, 186 |
| BORUZU | 56 | CARETOUCH PEN NEEDLES 32G X 4 MM | 169, 185, 186 |
| bosentan oral tablet | 57 | CARETOUCH PEN NEEDLES 32G X 5 MM | 169, 185, 186 |
| BOSULIF ORAL CAPSULE 100 MG, 50 MG | 58 | CARETOUCH PEN NEEDLES 33G X 4 MM | 169, 185, 186 |
| BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG..... | 58 | carglumic acid oral tablet soluble | 66 |
| BRAFTOVI ORAL CAPSULE 75 MG . | 114 | CAYSTON..... | 44 |
| BRUKINSA ORAL CAPSULE | 409 | | |
| BRUKINSA ORAL TABLET | 409 | | |
| C | | | |
| CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG..... | 62 | | |
| CALQUENCE | 9 | | |
| CAMCEVI..... | 207 | | |
| CAMZYOS | 223 | | |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | | | |
|----------------------------------|--------------------|--------------------------------|---------------|
| CIMZIA (1 SYRINGE) | 68, 69 | COMFORT EZ PEN NEEDLES 32G X 6 | |
| CIMZIA (2 SYRINGE) | 68, 69 | MM | 170, 185, 186 |
| CIMZIA SUBCUTANEOUS KIT 2 X 200 | | COMFORT EZ PEN NEEDLES 32G X 8 | |
| MG | 68, 69 | MM | 170, 185, 186 |
| CIMZIA-STARTER | 68, 69 | COMFORT EZ PEN NEEDLES 33G X 4 | |
| CLEVER CHOICE COMFORT EZ 29G X | | MM | 170, 185, 186 |
| 12MM | 169, 185, 186 | COMFORT EZ PEN NEEDLES 33G X 5 | |
| CLEVER CHOICE COMFORT EZ 33G X | | MM | 170, 185, 186 |
| 4 MM | 169, 185, 186 | COMFORT EZ PEN NEEDLES 33G X 6 | |
| CLICKFINE PEN NEEDLES 31G X 8 MM | | MM | 170, 185, 186 |
| | 169, 185, 186 | COMFORT EZ PEN NEEDLES 33G X 8 | |
| CLICKFINE PEN NEEDLES 32G X 4 MM | | MM | 170, 185, 186 |
| | 169, 185, 186 | COMFORT EZ PRO PEN NEEDLES 30G | |
| COMETRIQ (100 MG DAILY DOSE) | | X 8 MM..... | 170, 185, 186 |
| ORAL KIT 80 & 20 MG | 61 | COMFORT EZ PRO PEN NEEDLES 31G | |
| COMETRIQ (140 MG DAILY DOSE) | | X 4 MM..... | 170, 185, 186 |
| ORAL KIT 3 X 20 MG & 80 MG | 61 | COMFORT EZ PRO PEN NEEDLES 31G | |
| COMETRIQ (60 MG DAILY DOSE)..... | 61 | X 5 MM..... | 170, 185, 186 |
| COMFORT ASSIST INSULIN SYRINGE | | COMFORT TOUCH INSULIN PEN NEED | |
| 29G X 1/2..... | 169, 185, 186 | 31G X 4 MM..... | 170, 185, 186 |
| COMFORT ASSIST INSULIN SYRINGE | | COMFORT TOUCH INSULIN PEN NEED | |
| 31G X 5/16..... | 169, 185, 186 | 31G X 5 MM..... | 170, 185, 186 |
| COMFORT EZ INSULIN SYRINGE 27G | | COMFORT TOUCH INSULIN PEN NEED | |
| X 1/2..... | 169, 185, 186 | 31G X 6 MM..... | 170, 185, 186 |
| COMFORT EZ INSULIN SYRINGE 28G | | COMFORT TOUCH INSULIN PEN NEED | |
| X 1/2..... | 169, 185, 186 | 31G X 8 MM..... | 170, 185, 186 |
| COMFORT EZ INSULIN SYRINGE 29G | | COMFORT TOUCH INSULIN PEN NEED | |
| X 1/2..... | 169, 185, 186 | 32G X 4 MM..... | 170, 185, 186 |
| COMFORT EZ INSULIN SYRINGE 30G | | COMFORT TOUCH INSULIN PEN NEED | |
| X 1/2..... | 169, 170, 185, 186 | 32G X 5 MM..... | 170, 185, 186 |
| COMFORT EZ INSULIN SYRINGE 30G | | COMFORT TOUCH INSULIN PEN NEED | |
| X 5/16..... | 170, 185, 186 | 32G X 6 MM..... | 170, 185, 186 |
| COMFORT EZ INSULIN SYRINGE 31G | | COMFORT TOUCH INSULIN PEN NEED | |
| X 15/64..... | 170, 185, 186 | 32G X 8 MM..... | 170, 185, 186 |
| COMFORT EZ INSULIN SYRINGE 31G | | COPIKTRA..... | 102 |
| X 5/16..... | 170, 185, 186 | CORTROPHIN | 74, 75 |
| COMFORT EZ PEN NEEDLES 31G X 5 | | COSENTYX (300 MG DOSE)..... | 314, 315 |
| MM | 170, 185, 186 | COSENTYX SENSOREADY (300 MG) | |
| COMFORT EZ PEN NEEDLES 31G X 6 | | | 314, 315 |
| MM | 170, 185, 186 | COSENTYX SUBCUTANEOUS | |
| COMFORT EZ PEN NEEDLES 31G X 8 | | SOLUTION PREFILLED SYRINGE 75 | |
| MM | 170, 185, 186 | MG/0.5ML..... | 314, 315 |
| COMFORT EZ PEN NEEDLES 32G X 4 | | COSENTYX UNOREADY | 314, 315 |
| MM | 170, 185, 186 | COTELLIC | 73 |
| COMFORT EZ PEN NEEDLES 32G X 5 | | CRESEMBA ORAL | 192 |
| MM | 170, 185, 186 | | |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

CURITY ALCOHOL PREPS PAD 70 %
 170, 185, 186
 CURITY ALL PURPOSE SPONGES PAD
 2..... 170, 185, 186
 CURITY GAUZE PAD 2..... 170, 185, 186
 CURITY GAUZE SPONGE PAD 2..... 170,
 185, 186
 CURITY SPONGES PAD 2... 170, 185, 186
 CVS ALCOHOL PREP PADS PAD 70 %
 170, 185, 186
 CVS GAUZE PAD 2 170, 185, 186
 CVS GAUZE STERILE PAD 2 170, 185,
 186
 cvs isopropyl alcohol wipes 170, 185, 186
 CVS PREP PAD 70 % 170, 185, 186
 CYLTEZO (2 PEN) 16, 17
 CYLTEZO (2 SYRINGE) 16, 17
 CYLTEZO-CD/UC/HS STARTER.... 16, 17
 CYLTEZO-PSORIASIS/UV STARTER 16,
 17

D

dalfampridine er 81
 DANYELZA 238
 DANZITEN 243
 dasatinib oral tablet 100 mg, 140 mg, 20 mg,
 50 mg, 70 mg, 80 mg 83
 DATROWAY 84
 DAURISMO ORAL TABLET 100 MG, 25
 MG 147
 deferasirox granules 86, 87
 deferasirox oral tablet 86, 87
 DERMACEA GAUZE SPONGE PAD 2
 170, 185, 186
 DERMACEA IV DRAIN SPONGES PAD
 2..... 170, 185, 186
 DERMACEA NON-WOVEN SPONGES
 PAD 2..... 170, 185, 186
 DERMACEA TYPE VII GAUZE PAD 2
 170, 185, 186
 DIACOMIT ORAL CAPSULE 250 MG,
 500 MG 338
 DIACOMIT ORAL PACKET 250 MG, 500
 MG 338
 DIATHRIVE PEN NEEDLE 31G X 5 MM
 170, 185, 186

DIATHRIVE PEN NEEDLE 31G X 6 MM
 170, 185, 186
 DIATHRIVE PEN NEEDLE 31G X 8 MM
 171, 185, 186
 DIATHRIVE PEN NEEDLE 32G X 4 MM
 171, 185, 186
 diclofenac epolamine external 92
 diclofenac sodium external solution 2 % .. 91
 dimethyl fumarate oral capsule delayed
 release 120 mg, 240 mg 93
 dimethyl fumarate starter pack oral capsule
 delayed release therapy pack 93
 dronabinol 97
 DROPLET INSULIN SYRINGE 29G X 1/2
 171, 185, 186
 DROPLET INSULIN SYRINGE 30G X 1/2
 171, 185, 186
 DROPLET INSULIN SYRINGE 30G X
 15/64 171, 185, 186
 DROPLET INSULIN SYRINGE 30G X
 5/16 171, 185, 186
 DROPLET INSULIN SYRINGE 31G X
 15/64 171, 185, 186
 DROPLET INSULIN SYRINGE 31G X
 5/16 171, 185, 186
 DROPLET MICRON 34G X 3.5 MM... 171,
 185, 186
 DROPLET PEN NEEDLES 29G X 10MM
 171, 185, 186
 DROPLET PEN NEEDLES 29G X 12MM
 171, 185, 186
 DROPLET PEN NEEDLES 30G X 8 MM
 171, 185, 186
 DROPLET PEN NEEDLES 31G X 5 MM
 171, 185, 186
 DROPLET PEN NEEDLES 31G X 6 MM
 171, 185, 186
 DROPLET PEN NEEDLES 31G X 8 MM
 171, 185, 186
 DROPLET PEN NEEDLES 32G X 4 MM
 171, 185, 186
 DROPLET PEN NEEDLES 32G X 5 MM
 171, 185, 186
 DROPLET PEN NEEDLES 32G X 6 MM
 171, 185, 186

DROPLET PEN NEEDLES 32G X 8 MM
 171, 185, 186
 DROPSAFE ALCOHOL PREP PAD 70 %
 171, 185, 186
 DROPSAFE AUTOPROTECT DUO 31G X
 4 MM 171, 185, 186
 DROPSAFE AUTOPROTECT DUO 31G X
 8 MM 171, 185, 186
 DROPSAFE SAFETY PEN NEEDLES 31G
 X 5 MM..... 171, 185, 186
 DROPSAFE SAFETY PEN NEEDLES 31G
 X 6 MM..... 171, 185, 186
 DROPSAFE SAFETY SYRINGE/NEEDLE
 29G X 1/2..... 171, 185, 186
 DROPSAFE SAFETY SYRINGE/NEEDLE
 31G X 15/64..... 171, 185, 186
 DROPSAFE SAFETY SYRINGE/NEEDLE
 31G X 5/16..... 171, 185, 186
 droxidopa 98
 DRUG MART ULTRA COMFORT SYR
 29G X 1/2..... 171, 185, 186
 DRUG MART ULTRA COMFORT SYR
 30G X 5/16..... 171, 185, 186
 DRUG MART UNIFINE PENTIPS 31G X
 5 MM 171, 185, 186
 DUPIXENT SUBCUTANEOUS
 SOLUTION AUTO-INJECTOR .. 99, 101
 DUPIXENT SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE . 99,
 101

E

EASY COMFORT ALCOHOL PADS PAD
 172, 185, 186
 EASY COMFORT INSULIN SYRINGE
 29G X 5/16..... 172, 185, 186
 EASY COMFORT INSULIN SYRINGE
 30G X 1/2..... 172, 185, 186
 EASY COMFORT INSULIN SYRINGE
 30G X 5/16..... 172, 185, 186
 EASY COMFORT INSULIN SYRINGE
 31G X 1/2..... 172, 185, 186
 EASY COMFORT INSULIN SYRINGE
 31G X 5/16..... 172, 185, 186
 EASY COMFORT INSULIN SYRINGE
 32G X 5/16..... 172, 185, 186

EASY COMFORT PEN NEEDLES 29G X
 4MM 172, 185, 186
 EASY COMFORT PEN NEEDLES 29G X
 5MM 172, 185, 186
 EASY COMFORT PEN NEEDLES 31G X
 5 MM 172, 185, 186
 EASY COMFORT PEN NEEDLES 31G X
 6 MM 172, 185, 186
 EASY COMFORT PEN NEEDLES 31G X
 8 MM 172, 185, 186
 EASY COMFORT PEN NEEDLES 32G X
 4 MM 172, 185, 186
 EASY COMFORT PEN NEEDLES 33G X
 4 MM 172, 185, 186
 EASY COMFORT PEN NEEDLES 33G X
 5 MM 172, 185, 186
 EASY COMFORT PEN NEEDLES 33G X
 6 MM 172, 185, 186
 EASY GLIDE PEN NEEDLES 33G X 4
 MM 172, 185, 186
 EASY TOUCH ALCOHOL PREP
 MEDIUM PAD 70 %..... 172, 185, 186
 EASY TOUCH FLIPLOCK INSULIN SY
 29G X 1/2..... 172, 185, 186
 EASY TOUCH FLIPLOCK INSULIN SY
 30G X 1/2..... 172, 185, 186
 EASY TOUCH FLIPLOCK INSULIN SY
 30G X 5/16..... 172, 185, 186
 EASY TOUCH FLIPLOCK INSULIN SY
 31G X 5/16..... 172, 185, 186
 EASY TOUCH FLIPLOCK SAFETY SYR
 27G X 1/2..... 172, 185, 186
 EASY TOUCH INSULIN BARRELS U-
 100 1 ML..... 172, 185, 186
 EASY TOUCH INSULIN SAFETY SYR
 29G X 1/2..... 172, 185, 186
 EASY TOUCH INSULIN SAFETY SYR
 30G X 1/2..... 172, 185, 186
 EASY TOUCH INSULIN SAFETY SYR
 30G X 5/16..... 172, 185, 186
 EASY TOUCH INSULIN SYRINGE 27G
 X 1/2..... 172, 185, 186
 EASY TOUCH INSULIN SYRINGE 27G
 X 5/8..... 172, 185, 186
 EASY TOUCH INSULIN SYRINGE 28G
 X 1/2..... 172, 185, 186

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | | | |
|---|---------------|--|---------------|
| EASY TOUCH INSULIN SYRINGE 29G X 1/2..... | 172, 185, 186 | ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML..... | 109 |
| EASY TOUCH INSULIN SYRINGE 30G X 1/2..... | 172, 185, 186 | eltrombopag olamine oral packet 12.5 mg, 25 mg | 111, 112 |
| EASY TOUCH INSULIN SYRINGE 30G X 5/16..... | 173, 185, 186 | eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg | 111, 112 |
| EASY TOUCH INSULIN SYRINGE 31G X 5/16..... | 173, 185, 186 | EMBECTA AUTOSHIELD DUO 30G X 5 MM | 173, 185, 186 |
| EASY TOUCH PEN NEEDLES 29G X 12MM | 173, 185, 186 | EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64 | 173, 185, 186 |
| EASY TOUCH PEN NEEDLES 30G X 5 MM | 173, 185, 186 | EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16 | 173, 185, 186 |
| EASY TOUCH PEN NEEDLES 30G X 6 MM | 173, 185, 186 | EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2..... | 173, 185, 186 |
| EASY TOUCH PEN NEEDLES 30G X 8 MM | 173, 185, 186 | EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64..... | 173, 185, 186 |
| EASY TOUCH PEN NEEDLES 31G X 5 MM | 173, 185, 186 | EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16..... | 173, 185, 186 |
| EASY TOUCH PEN NEEDLES 31G X 6 MM | 173, 185, 186 | EMBECTA INSULIN SYRINGE 28G X 1/2 | 173, 185, 186 |
| EASY TOUCH PEN NEEDLES 31G X 8 MM | 173, 185, 186 | EMBECTA INSULIN SYRINGE U-100 27G X 5/8..... | 173, 185, 186 |
| EASY TOUCH PEN NEEDLES 32G X 4 MM | 173, 185, 186 | EMBECTA INSULIN SYRINGE U-500 | 173, 185, 186 |
| EASY TOUCH PEN NEEDLES 32G X 5 MM | 173, 185, 186 | EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM..... | 173, 185, 186 |
| EASY TOUCH PEN NEEDLES 32G X 6 MM | 173, 185, 186 | EMBECTA PEN NEEDLE NANO 32G X 4 MM | 173, 185, 186 |
| EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM..... | 173, 185, 186 | EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM..... | 173, 185, 186 |
| EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM..... | 173, 185, 186 | EMBECTA PEN NEEDLE ULTRAFINE 31G X 5 MM..... | 173, 185, 186 |
| EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM..... | 173, 185, 186 | EMBECTA PEN NEEDLE ULTRAFINE 31G X 8 MM..... | 173, 185, 186 |
| EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2..... | 173, 185, 186 | EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM..... | 173, 185, 186 |
| EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2..... | 173, 185, 186 | EMBRACE PEN NEEDLES 29G X 12MM | 173, 185, 186 |
| EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16..... | 173, 185, 186 | EMBRACE PEN NEEDLES 30G X 5 MM | 173, 185, 186 |
| EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16..... | 173, 185, 186 | EMBRACE PEN NEEDLES 30G X 8 MM | 174, 185, 186 |
| ELAHERE | 234 | EMBRACE PEN NEEDLES 31G X 5 MM | 174, 185, 186 |
| ELIGARD..... | 208 | | |

EMBRACE PEN NEEDLES 31G X 6 MM
 174, 185, 186
 EMBRACE PEN NEEDLES 31G X 8 MM
 174, 185, 186
 EMBRACE PEN NEEDLES 32G X 4 MM
 174, 185, 186
 EMGALITY 142
 EMGALITY (300 MG DOSE) 142
 EMRELIS 350
 ENBREL MINI 126, 127
 ENBREL SUBCUTANEOUS SOLUTION
 25 MG/0.5ML 126, 127
 ENBREL SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 126, 127
 ENBREL SURECLICK SUBCUTANEOUS
 SOLUTION AUTO-INJECTOR 126, 127
 ENSACOVE ORAL CAPSULE 100 MG,
 25 MG 115
 EPCLUSA ORAL PACKET 150-37.5 MG,
 200-50 MG 327
 EPCLUSA ORAL TABLET 327
 EPIDIOLEX 63
 EPKINLY 119
 EQL ALCOHOL SWABS PAD 70 %... 174,
 185, 186
 EQL GAUZE PAD 2 174, 185, 186
 EQL INSULIN SYRINGE 30G X 5/16. 174,
 185, 186
 ERBITUX 70
 ERIVEDGE 404
 ERLEADA ORAL TABLET 240 MG, 60
 MG 28
 erlotinib hcl oral tablet 100 mg, 150 mg, 25
 mg 124
 everolimus oral tablet 10 mg, 2.5 mg, 5 mg,
 7.5 mg 128
 everolimus oral tablet soluble 129
 EXEL COMFORT POINT INSULIN SYR
 29G X 1/2 174, 185, 186
 EXEL COMFORT POINT INSULIN SYR
 30G X 5/16 174, 185, 186
 EXEL COMFORT POINT PEN NEEDLE
 29G X 12MM 174, 185, 186
 EXXUA 145
 EXXUA TITRATION PACK 145

F
 FASENRA 50, 51
 FASENRA PEN 50, 51
 fentanyl citrate buccal lozenge on a handle
 133
 FIFTY50 PEN NEEDLES 31G X 5 MM
 174, 185, 186
 FIFTY50 PEN NEEDLES 31G X 8 MM
 174, 185, 186
 FIFTY50 PEN NEEDLES 32G X 4 MM
 174, 185, 186
 FIFTY50 PEN NEEDLES 32G X 6 MM
 174, 185, 186
 fingolimod hcl 138
 FINTEPLA 132
 FOTIVDA 361
 FRUZAQLA ORAL CAPSULE 1 MG, 5
 MG 140
 FYARRO 324
G
 GAUZE PADS PAD 2 174, 185, 186
 GAUZE TYPE VII MEDI-PAK PAD 2 174,
 185, 186
 GAVRETO 284
 gefitinib 144
 GILOTRIF 20
 glatiramer acetate subcutaneous solution
 prefilled syringe 20 mg/ml, 40 mg/ml 148
 glatopa subcutaneous solution prefilled
 syringe 20 mg/ml, 40 mg/ml 148
 GLOBAL ALCOHOL PREP EASE 174,
 185, 186
 GLOBAL EASE INJECT PEN NEEDLES
 29G X 12MM 174, 185, 186
 GLOBAL EASE INJECT PEN NEEDLES
 31G X 5 MM 174, 185, 186
 GLOBAL EASE INJECT PEN NEEDLES
 31G X 8 MM 174, 185, 186
 GLOBAL EASE INJECT PEN NEEDLES
 32G X 4 MM 174, 185, 186
 GLOBAL EASY GLIDE INSULIN SYR
 31G X 15/64 174, 185, 186
 GLOBAL INJECT EASE INSULIN SYR
 30G X 1/2 174, 185, 186
 GLUCOPRO INSULIN SYRINGE 30G X
 1/2 174, 185, 186

GLUCOPRO INSULIN SYRINGE 30G X 5/16 174, 185, 186
 GLUCOPRO INSULIN SYRINGE 31G X 5/16 174, 185, 186
 GNP ALCOHOL SWABS PAD.... 174, 185, 186
 GNP CLICKFINE PEN NEEDLES 31G X 6 MM 174, 185, 186
 GNP CLICKFINE PEN NEEDLES 31G X 8 MM 174, 185, 186
 GNP INSULIN SYRINGE 28G X 1/2 .. 174, 185, 186
 GNP INSULIN SYRINGE 29G X 1/2 .. 174, 185, 186
 GNP INSULIN SYRINGE 30G X 5/16 174, 185, 186
 GNP INSULIN SYRINGES 29GX1/2.. 174, 185, 186
 GNP INSULIN SYRINGES 30G X 5/16 174, 185, 186
 GNP INSULIN SYRINGES 30GX5/16 174, 185, 186
 GNP INSULIN SYRINGES 31GX5/16 174, 185, 186
 GNP PEN NEEDLES 31G X 5 MM 174, 185, 186
 GNP PEN NEEDLES 32G X 4 MM 174, 185, 186
 GNP PEN NEEDLES 32G X 6 MM 174, 185, 186
 GNP STERILE GAUZE PAD 2.... 174, 185, 186
 GNP ULTRA COM INSULIN SYRINGE 29G X 1/2..... 175, 185, 186
 GNP ULTRA COM INSULIN SYRINGE 30G X 5/16..... 175, 185, 186
 GOMEKLI ORAL CAPSULE 1 MG, 2 MG 233
 GOMEKLI ORAL TABLET SOLUBLE233
 GOODSENSE ALCOHOL SWABS PAD 70 % 175, 185, 186
 GOODSENSE CLICKFINE PEN NEEDLE 31G X 5 MM..... 175, 185, 186
 GOODSENSE PEN NEEDLE PENFINE 31G X 8 MM..... 175, 185, 186

H
 HADLIMA..... 18, 19
 HADLIMA PUSHTOUCH..... 18, 19
 HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT 60
 HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG 201
 HARVONI ORAL TABLET 201
 HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16..... 175, 185, 186
 HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16..... 175, 185, 186
 HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM..... 175, 185, 186
 HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM..... 175, 185, 186
 HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM..... 175, 185, 186
 HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM..... 175, 185, 186
 HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM..... 175, 185, 186
 HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM..... 175, 185, 186
 HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM..... 175, 185, 186
 HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM..... 175, 185, 186
 H-E-B INCONTROL ALCOHOL PAD 175, 185, 186
 H-E-B INCONTROL PEN NEEDLES 29G X 12MM..... 175, 185, 186
 H-E-B INCONTROL PEN NEEDLES 31G X 5 MM..... 175, 185, 186
 H-E-B INCONTROL PEN NEEDLES 31G X 6 MM..... 175, 185, 186
 H-E-B INCONTROL PEN NEEDLES 31G X 8 MM..... 175, 185, 186
 H-E-B INCONTROL PEN NEEDLES 31G X 8 MM..... 175, 185, 186
 H-E-B INCONTROL PEN NEEDLES 32G X 4 MM..... 175, 185, 186
 HERCEPTIN HYLECTA..... 376
 HERNEXEOS 413
 HM STERILE ALCOHOL PREP PAD 175, 185, 186
 HM STERILE PADS PAD 2.. 175, 185, 186

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | | | |
|---|---------------|--|--------------------|
| HM ULTICARE INSULIN SYRINGE 30G X 1/2..... | 175, 185, 186 | INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM..... | 175, 185, 186 |
| HM ULTICARE INSULIN SYRINGE 31G X 5/16..... | 175, 185, 186 | INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM..... | 175, 185, 186 |
| HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM..... | 175, 185, 186 | INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM..... | 175, 185, 186 |
| HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT..... | 12, 13 | INCRELEX..... | 224 |
| HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML..... | 12, 13 | infliximab..... | 165, 166 |
| HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT..... | 12, 13 | INGREZZA ORAL CAPSULE..... | 397 |
| HUMIRA-PED<40KG CROHNS STARTER..... | 12, 13 | INGREZZA ORAL CAPSULE SPRINKLE..... | 397 |
| HUMIRA-PED>/=40KG CROHNS STARTER..... | 12, 13 | INGREZZA ORAL CAPSULE THERAPY PACK..... | 397 |
| HUMIRA-PED>/=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT..... | 12, 13 | INLURIYO..... | 163 |
| HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT..... | 12, 13 | INLYTA ORAL TABLET 1 MG, 5 MG.. | 42 |
| HUMIRA-PSORIASIS/UEVIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT..... | 12, 13 | INQOVI..... | 85 |
| HYRNUO..... | 320 | INREBIC..... | 131 |
| I | | INSULIN SYRINGE 29G X 1/2 ... | 175, 185, 186 |
| IBRANCE..... | 264 | INSULIN SYRINGE 30G X 5/16 . | 175, 185, 186 |
| IBTROZI..... | 344 | INSULIN SYRINGE 31G X 5/16 . | 175, 185, 186 |
| icatibant acetate..... | 158 | INSULIN SYRINGE/NEEDLE 27G X 1/2..... | 176, 185, 186 |
| ICLUSIG..... | 282 | INSULIN SYRINGE/NEEDLE 28G X 1/2..... | 176, 185, 186 |
| IDHIFA..... | 113 | INSULIN SYRINGE-NEEDLE U-100 27G X 1/2..... | 175, 185, 186 |
| imatinib mesylate oral tablet 100 mg, 400 mg..... | 160 | INSULIN SYRINGE-NEEDLE U-100 28G X 1/2..... | 175, 185, 186 |
| IMBRUVICA ORAL CAPSULE 140 MG, 70 MG..... | 157 | INSULIN SYRINGE-NEEDLE U-100 30G X 5/16..... | 175, 185, 186 |
| IMBRUVICA ORAL SUSPENSION..... | 157 | INSULIN SYRINGE-NEEDLE U-100 31G X 1/4..... | 175, 176, 185, 186 |
| IMBRUVICA ORAL TABLET..... | 157 | INSULIN SYRINGE-NEEDLE U-100 31G X 5/16..... | 176, 185, 186 |
| IMDELLTRA..... | 346 | INSUPEN PEN NEEDLES 29G X 12MM..... | 176, 185, 186 |
| IMJUDO..... | 378 | INSUPEN PEN NEEDLES 31G X 5 MM..... | 176, 185, 186 |
| IMKELDI..... | 161 | INSUPEN PEN NEEDLES 31G X 8 MM..... | 176, 185, 186 |
| IMPAVIDO..... | 232 | INSUPEN PEN NEEDLES 32G X 4 MM..... | 176, 185, 186 |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

INSUPEN PEN NEEDLES 33G X 4 MM
 176, 185, 186
 INSUPEN SENSITIVE 32G X 6 MM... 176,
 185, 186
 INSUPEN SENSITIVE 32G X 8 MM... 176,
 185, 186
 INSUPEN ULTRAFIN 30G X 8 MM... 176,
 185, 186
 INSUPEN ULTRAFIN 31G X 6 MM... 176,
 185, 186
 INSUPEN ULTRAFIN 31G X 8 MM... 176,
 185, 186
 INSUPEN32G EXTR3ME 32G X 6 MM
 176, 185, 186
 ITOVEBI ORAL TABLET 3 MG, 9 MG
 164
 IWILFIN 103
J
 J & J GAUZE PAD 2..... 176, 185, 186
 JAKAFI..... 312
 JASCAYD..... 239, 240
 javygtor oral tablet 313
 JAYPIRCA ORAL TABLET 100 MG, 50
 MG 280
 JEMPERLI..... 96
 JYNARQUE ORAL TABLET 368
K
 KALYDECO..... 193
 KENDALL HYDROPHILIC FOAM
 DRESS PAD 2 176, 185, 186
 KENDALL HYDROPHILIC FOAM PLUS
 PAD 2..... 176, 185, 186
 KERENDIA 137
 KESIMPTA..... 254
 KEYTRUDA INTRAVENOUS
 SOLUTION..... 271
 KEYTRUDA QLEX..... 272
 KIMMTRAK 348
 KINERET SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 26, 27
 KINRAY INSULIN SYRINGE 29G X 1/2
 176, 185, 186
 KISQALI (200 MG DOSE) 294
 KISQALI (400 MG DOSE) 294
 KISQALI (600 MG DOSE) 294
 KISQALI FEMARA (200 MG DOSE) .. 295

KISQALI FEMARA (400 MG DOSE) .. 295
 KISQALI FEMARA (600 MG DOSE) .. 295
 KMART VALU INSULIN SYRINGE 29G
 U-100 1 ML 176, 185, 186
 KMART VALU INSULIN SYRINGE 30G
 U-100 0.3 ML 176, 185, 186
 KMART VALU INSULIN SYRINGE 30G
 U-100 1 ML 176, 185, 186
 KOMZIFTI 411
 KOSELUGO ORAL CAPSULE 10 MG, 25
 MG 319
 KOSELUGO ORAL CAPSULE
 SPRINKLE 5 MG, 7.5 MG..... 319
 KRAZATI..... 11
 KROGER INSULIN SYRINGE 30G X 5/16
 176, 185, 186
 KROGER PEN NEEDLES 29G X 12MM
 176, 185, 186
 KROGER PEN NEEDLES 31G X 6 MM
 176, 185, 186
 KYNMOBI 30
L
 LANREOTIDE ACETATE 197
 lapatinib ditosylate 198
 LAZCLUZE ORAL TABLET 240 MG, 80
 MG 200
 LEADER INSULIN SYRINGE 28G X 1/2
 176, 185, 186
 LEADER UNIFINE PENTIPS 31G X 5
 MM 176, 185, 186
 LEADER UNIFINE PENTIPS 32G X 4
 MM 176, 185, 186
 LEADER UNIFINE PENTIPS PLUS 31G
 X 5 MM..... 176, 185, 186
 LEADER UNIFINE PENTIPS PLUS 31G
 X 8 MM..... 176, 185, 186
 ledipasvir-sofosbuvir..... 201
 lenalidomide..... 202
 LENVIMA (10 MG DAILY DOSE) 203
 LENVIMA (12 MG DAILY DOSE) 203
 LENVIMA (14 MG DAILY DOSE) 203
 LENVIMA (18 MG DAILY DOSE) 203
 LENVIMA (20 MG DAILY DOSE) 203
 LENVIMA (24 MG DAILY DOSE) 203
 LENVIMA (4 MG DAILY DOSE) 203
 LENVIMA (8 MG DAILY DOSE) 203

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | |
|--|--------------------------------------|
| LEUPROLIDE ACETATE (3 MONTH) 206 | LYTGOBI (20 MG DAILY DOSE)..... 141 |
| leuprolide acetate injection 205 | M |
| l-glutamine oral packet 212 | MAGELLAN INSULIN SAFETY SYR |
| lidocaine external ointment 5 % 213 | 29G X 1/2..... 176, 185, 186 |
| lidocaine-prilocaine external cream..... 214 | MAGELLAN INSULIN SAFETY SYR |
| LITETOUCH INSULIN SYRINGE 28G X | 30G X 5/16..... 177, 185, 186 |
| 1/2 176, 185, 186 | MARGENZA 221 |
| LITETOUCH INSULIN SYRINGE 29G X | MAVENCLAD (10 TABS) 71 |
| 1/2 176, 185, 186 | MAVENCLAD (4 TABS) 71 |
| LITETOUCH INSULIN SYRINGE 30G X | MAVENCLAD (5 TABS) 71 |
| 5/16 176, 185, 186 | MAVENCLAD (6 TABS) 71 |
| LITETOUCH INSULIN SYRINGE 31G X | MAVENCLAD (7 TABS) 71 |
| 5/16 176, 185, 186 | MAVENCLAD (8 TABS) 71 |
| LITETOUCH PEN NEEDLES 29G X | MAVENCLAD (9 TABS) 71 |
| 12.7MM 176, 185, 186 | MAVYRET ORAL TABLET..... 149, 150 |
| LITETOUCH PEN NEEDLES 31G X 5 | MAXICOMFORT II PEN NEEDLE 31G X |
| MM 176, 185, 186 | 6 MM 177, 185, 186 |
| LITETOUCH PEN NEEDLES 31G X 6 | MAXI-COMFORT INSULIN SYRINGE |
| MM 176, 185, 186 | 28G X 1/2..... 177, 185, 186 |
| LITETOUCH PEN NEEDLES 31G X 8 | MAXI-COMFORT SAFETY PEN |
| MM 176, 185, 186 | NEEDLE 29G X 5MM 177, 185, 186 |
| LITETOUCH PEN NEEDLES 32G X 4 | MAXI-COMFORT SAFETY PEN |
| MM 176, 185, 186 | NEEDLE 29G X 8MM 177, 185, 186 |
| LIVTENCITY..... 222 | MAXICOMFORT SYR 27G X 1/2 177, 185, |
| LONSURF ORAL TABLET 15-6.14 MG, | 186 |
| 20-8.19 MG..... 381 | MAYZENT ORAL TABLET 0.25 MG, 1 |
| LOQTORZI..... 370 | MG, 2 MG..... 323 |
| LORBRENA ORAL TABLET 100 MG, 25 | MAYZENT STARTER PACK..... 323 |
| MG 217 | MEDIC INSULIN SYRINGE 30G X 5/16 |
| LUMAKRAS ORAL TABLET 120 MG, | 177, 185, 186 |
| 240 MG, 320 MG..... 337 | MEDICINE SHOPPE PEN NEEDLES 29G |
| LUNSUMIO 236 | X 12MM..... 177, 185, 186 |
| LUNSUMIO VELO..... 236 | MEDICINE SHOPPE PEN NEEDLES 31G |
| LUPRON DEPOT (1-MONTH)..... 209, 210 | X 8 MM..... 177, 185, 186 |
| LUPRON DEPOT (3-MONTH)..... 209, 210 | MEDPURA ALCOHOL PADS 70 % |
| LUPRON DEPOT (4-MONTH)..... 209, 210 | EXTERNAL 177, 185, 186 |
| LUPRON DEPOT (6-MONTH)..... 209, 210 | MEIJER ALCOHOL SWABS PAD 70 % |
| LUPRON DEPOT-PED (3-MONTH).... 211 | 177, 185, 186 |
| LUPRON DEPOT-PED (6-MONTH).... 211 | MEIJER PEN NEEDLES 29G X 12MM |
| LUTRATE DEPOT 206 | 177, 185, 186 |
| LYNOZYFIC INTRAVENOUS | MEIJER PEN NEEDLES 31G X 6 MM 177, |
| SOLUTION 200 MG/10ML, 5 | 185, 186 |
| MG/2.5ML 215 | MEIJER PEN NEEDLES 31G X 8 MM 177, |
| LYNPARZA ORAL TABLET 255 | 185, 186 |
| LYTGOBI (12 MG DAILY DOSE)..... 141 | MEKINIST ORAL SOLUTION |
| LYTGOBI (16 MG DAILY DOSE)..... 141 | RECONSTITUTED 373 |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | | | |
|---|------------------|--|---------------|
| MEKINIST ORAL TABLET 0.5 MG, 2 MG | 374 | nilotinib hcl oral capsule 150 mg, 200 mg, 50 mg | 242 |
| MEKTOVI | 55 | NINLARO..... | 195 |
| metyrosine..... | 229 | nintedanib esylate..... | 244, 245 |
| MICRODOT PEN NEEDLE 31G X 6 MM | 177, 185, 186 | nitisinone..... | 249 |
| MICRODOT PEN NEEDLE 32G X 4 MM | 177, 185, 186 | NIVESTYM..... | 136 |
| MICRODOT PEN NEEDLE 33G X 4 MM | 177, 185, 186 | NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN- INJECTOR..... | 330, 331 |
| mifepristone oral tablet 300 mg | 231 | NOVOFINE AUTOCOVER 30G X 8 MM | 178, 185, 186 |
| MIPLYFFA..... | 33 | NOVOFINE PEN NEEDLE 32G X 6 MM | 178, 185, 186 |
| MIRASORB SPONGES 2..... | 177, 185, 186 | NOVOFINE PLUS PEN NEEDLE 32G X 4 MM | 178, 185, 186 |
| MM PEN NEEDLES 31G X 6 MM | 177, 185, 186 | NOVOTWIST PEN NEEDLE 32G X 5 MM | 178, 185, 186 |
| MM PEN NEEDLES 32G X 4 MM | 177, 185, 186 | NUBEQA | 82 |
| modafinil oral tablet 100 mg, 200 mg..... | 237 | NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR | 226, 227, 228 |
| MODEYSO..... | 95 | NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML..... | 226, 227, 228 |
| MONOJECT INSULIN SYRINGE 25G X 5/8 | 177, 185, 186 | NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED..... | 226, 227, 228 |
| MONOJECT INSULIN SYRINGE 27G X 1/2 | 177, 185, 186 | NUEDEXTA..... | 90 |
| MONOJECT INSULIN SYRINGE 28G X 1/2 | 177, 185, 186 | NUPLAZID ORAL CAPSULE..... | 277 |
| MONOJECT INSULIN SYRINGE 29G X 1/2 | 177, 185, 186 | NUPLAZID ORAL TABLET 10 MG.... | 277 |
| MONOJECT INSULIN SYRINGE 30G X 5/16 | 177, 185, 186 | NURTEC..... | 300, 301 |
| MONOJECT INSULIN SYRINGE 31G X 5/16 | 177, 185, 186 | NYVEPRIA | 267 |
| MONOJECT INSULIN SYRINGE U-100 1 ML..... | 177, 185, 186 | O | |
| MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2 | 177, 185, 186 | ODOMZO | 333 |
| MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2 | 177, 185, 186 | OFEV | 244, 245 |
| MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16 | 177, 185, 186 | OGIVRI..... | 375 |
| MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR | 153 | OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG..... | 248 |
| MS INSULIN SYRINGE 31G X 5/16... 177, 185, 186 | | OJEMDA ORAL SUSPENSION RECONSTITUTED..... | 371 |
| N | | OJEMDA ORAL TABLET | 371 |
| NERLYNX | 241 | OJJAARA | 235 |
| NIKTIMVO | 41 | ONAPGO..... | 29 |
| | | ONUREG..... | 43 |
| | | OPDIVO | 250 |
| | | OPDIVO QVANTIG | 251 |
| | | OPDUALAG..... | 252 |
| | | OPSUMIT | 220 |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | | | |
|--|------------------|---|---------------|
| ORENCIA CLICKJECT..... | 4, 5 | PENTIPS 31G X 8 MM (RX). | 178, 185, 186 |
| ORENCIA INTRAVENOUS | 2, 3 | PENTIPS 32G X 4 MM (RX). | 178, 185, 186 |
| ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 4, 5 | PENTIPS GENERIC PEN NEEDLES 29G X 12MM..... | 178, 185, 186 |
| ORFADIN ORAL SUSPENSION..... | 249 | PENTIPS GENERIC PEN NEEDLES 31G X 6 MM..... | 178, 185, 186 |
| ORGOVYX..... | 289 | PENTIPS GENERIC PEN NEEDLES 32G X 6 MM..... | 178, 185, 186 |
| ORLISSA ORAL TABLET 150 MG, 200 MG | 105, 106 | PHARMACIST CHOICE ALCOHOL PAD | 178, 185, 186 |
| ORKAMBI ORAL TABLET | 219 | PIP PEN NEEDLES 31G X 5MM 31G X 5 MM | 178, 185, 186 |
| ORSERDU ORAL TABLET 345 MG, 86 MG | 104 | PIP PEN NEEDLES 32G X 4MM 32G X 4 MM | 178, 185, 186 |
| OSEVELT | 88 | PIQRAY (200 MG DAILY DOSE)..... | 22 |
| OTEZLA | 31, 32 | PIQRAY (250 MG DAILY DOSE)..... | 22 |
| OTEZLA XR | 31, 32 | PIQRAY (300 MG DAILY DOSE)..... | 22 |
| OTEZLA/OTEZLA XR INITIATION PK | 31, 32 | pirfenidone oral capsule | 278, 279 |
| oxandrolone oral | 262 | pirfenidone oral tablet 267 mg, 534 mg, 801 mg | 278, 279 |
| OZEMPIC | 152 | PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO- INJECTOR..... | 189 |
| OZEMPIC (0.25 OR 0.5 MG/DOSE)..... | 152 | PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 189 |
| OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN- INJECTOR 4 MG/3ML | 152 | PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR | 189 |
| OZEMPIC (2 MG/DOSE) | 152 | PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 189 |
| P | | pomalidomide | 281 |
| pazopanib hcl oral tablet 200 mg, 400 mg | 266 | POMALYST | 281 |
| PC UNIFINE PENTIPS 31G X 5 MM.. | 178, 185, 186 | posaconazole oral tablet delayed release | 283 |
| PC UNIFINE PENTIPS 31G X 6 MM.. | 178, 185, 186 | PRECISION SURE-DOSE SYRINGE 30G X 5/16..... | 178, 185, 186 |
| PC UNIFINE PENTIPS 31G X 8 MM.. | 178, 185, 186 | PREFERRED PLUS INSULIN SYRINGE 28G X 1/2..... | 178, 185, 186 |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 269 | PREFERRED PLUS INSULIN SYRINGE 29G X 1/2..... | 178, 185, 186 |
| PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 269 | PREFERRED PLUS INSULIN SYRINGE 30G X 5/16..... | 178, 185, 186 |
| PEMAZYRE | 273 | PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM..... | 178, 185, 186 |
| PEN NEEDLE/5-BEVEL TIP 31G X 8 MM | 178, 185, 186 | PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM..... | 178, 185, 186 |
| PEN NEEDLES 30G X 5 MM (OTC)... | 178, 185, 186 | | |
| PEN NEEDLES 30G X 8 MM | 178, 185, 186 | | |
| PEN NEEDLES 32G X 5 MM | 178, 185, 186 | | |
| penicillamine oral tablet..... | 274, 275 | | |
| PENTIPS 29G X 12MM (RX) | 178, 185, 186 | | |
| PENTIPS 31G X 5 MM (RX). | 178, 185, 186 | | |

PREVENT DROPSAFE PEN NEEDLES

31G X 8 MM..... 178, 185, 186

PREVENT SAFETY PEN NEEDLES 31G

X 6 MM..... 178, 185, 186

PREVENT SAFETY PEN NEEDLES 31G

X 8 MM..... 178, 185, 186

PREVYMIS ORAL TABLET 204

PRO COMFORT ALCOHOL PAD 70 %

..... 178, 185, 186

PRO COMFORT INSULIN SYRINGE 30G

X 1/2..... 178, 185, 186

PRO COMFORT INSULIN SYRINGE 30G

X 5/16..... 178, 185, 186

PRO COMFORT INSULIN SYRINGE 31G

X 5/16..... 178, 185, 186

PRO COMFORT PEN NEEDLES 32G X 4

MM 178, 185, 186

PRO COMFORT PEN NEEDLES 32G X 5

MM 178, 185, 186

PRO COMFORT PEN NEEDLES 32G X 6

MM 178, 185, 186

PRO COMFORT PEN NEEDLES 32G X 8

MM 178, 185, 186

PRODIGY INSULIN SYRINGE 28G X 1/2

..... 178, 185, 186

PRODIGY INSULIN SYRINGE 31G X

5/16 178, 185, 186

PURE COMFORT ALCOHOL PREP PAD

..... 178, 185, 186

PURE COMFORT PEN NEEDLE 32G X 4

MM 178, 185, 186

PURE COMFORT PEN NEEDLE 32G X 5

MM 178, 185, 186

PURE COMFORT PEN NEEDLE 32G X 6

MM 178, 185, 186

PURE COMFORT PEN NEEDLE 32G X 8

MM 178, 185, 186

PURE COMFORT SAFETY PEN NEEDLE

31G X 5 MM..... 178, 185, 186

PURE COMFORT SAFETY PEN NEEDLE

31G X 6 MM..... 179, 185, 186

PURE COMFORT SAFETY PEN NEEDLE

32G X 4 MM..... 179, 185, 186

PX SHORTLENGTH PEN NEEDLES 31G

X 8 MM..... 179, 185, 186

pyrimethamine oral 285

Q

QC ALCOHOL..... 179, 185, 186

QC ALCOHOL SWABS PAD 70 % 179,

185, 186

QC BORDER ISLAND GAUZE PAD 2

..... 179, 185, 186

QINLOCK..... 304

QUICK TOUCH INSULIN PEN NEEDLE

29G X 12.7MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

31G X 4 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

31G X 5 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

31G X 6 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

31G X 8 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

32G X 4 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

32G X 5 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

32G X 6 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

32G X 8 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

33G X 4 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

33G X 5 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

33G X 6 MM..... 179, 185, 186

QUICK TOUCH INSULIN PEN NEEDLE

33G X 8 MM..... 179, 185, 186

quinine sulfate oral..... 286

QULIPTA 37

R

RA ALCOHOL SWABS PAD 70 % 179,

185, 186

RA INSULIN SYRINGE 29G X 1/2..... 179,

185, 186

RA INSULIN SYRINGE 30G X 5/16... 179,

185, 186

ra isopropyl alcohol wipes 179, 185, 186

RA PEN NEEDLES 31G X 5 MM 179, 185,

186

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | |
|--|---|
| RA PEN NEEDLES 31G X 8 MM 179, 185, 186 | REVCIVI..... 107 |
| RA STERILE PAD 2 179, 185, 186 | REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG..... 293 |
| RALDESY 377 | REZDIFFRA..... 291 |
| RAYA SURE PEN NEEDLE 29G X 12MM 179, 185, 186 | REZLIDHIA 256 |
| RAYA SURE PEN NEEDLE 31G X 4 MM 179, 185, 186 | REZUROCK..... 47 |
| RAYA SURE PEN NEEDLE 31G X 5 MM 179, 185, 186 | RINVOQ..... 385, 386 |
| RAYA SURE PEN NEEDLE 31G X 6 MM 179, 185, 186 | RINVOQ LQ..... 385, 386 |
| RAYA SURE PEN NEEDLE 31G X 8 MM 179, 185, 186 | RITUXAN HYCELA 307 |
| REALITY INSULIN SYRINGE 28G X 1/2 179, 185, 186 | ROMVIMZA 403 |
| REALITY INSULIN SYRINGE 29G X 1/2 179, 185, 186 | ROZLYTREK ORAL CAPSULE 100 MG, 200 MG 116 |
| REALITY SWABS PAD..... 179, 185, 186 | ROZLYTREK ORAL PACKET 117 |
| RELION ALCOHOL SWABS PAD 179, 185, 186 | RUBRACA 311 |
| RELION ALCOHOL SWABS PAD 70 % 179, 185, 186 | RYBELSUS 152 |
| RELI-ON INSULIN SYRINGE 29G 0.3 ML..... 179, 185, 186 | RYBELSUS (FORMULATION R2)..... 152 |
| RELION INSULIN SYRINGE 31G X 15/64 179, 185, 186 | RYBREVANT 25 |
| RELION MINI PEN NEEDLES 31G X 6 MM 179, 185, 186 | RYBREVANT FASPRO..... 24 |
| RELION PEN NEEDLES 29G X 12MM 179, 185, 186 | RYDAPT..... 230 |
| RELION PEN NEEDLES 31G X 6 MM179, 185, 186 | RYTELO..... 162 |
| RELION PEN NEEDLES 31G X 8 MM179, 185, 186 | S |
| RESTORE CONTACT LAYER PAD 2 179, 185, 186 | SAFETY INSULIN SYRINGES 29G X 1/2 179, 185, 186 |
| RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML 120, 121 | SAFETY INSULIN SYRINGES 30G X 1/2 180, 185, 186 |
| RETEVMO ORAL CAPSULE 40 MG, 80 MG 318 | SAFETY INSULIN SYRINGES 30G X 5/16 180, 185, 186 |
| RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG 318 | SAFETY PEN NEEDLES 30G X 5 MM 180, 185, 186 |
| | SAFETY PEN NEEDLES 30G X 8 MM 180, 185, 186 |
| | sapropterin dihydrochloride oral tablet... 313 |
| | SB ALCOHOL PREP PAD 70 %.. 180, 185, 186 |
| | SB INSULIN SYRINGE 29G X 1/2 180, 185, 186 |
| | SB INSULIN SYRINGE 30G X 5/16 ... 180, 185, 186 |
| | SB INSULIN SYRINGE 31G X 5/16 ... 180, 185, 186 |
| | SCSEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG..... 34 |
| | SECURESAFE INSULIN SYRINGE 29G X 1/2..... 180, 185, 186 |
| | SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM..... 180, 185, 186 |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | | | |
|---|--------------------|---|---------------|
| SELARSDI | 389, 390, 391, 392 | SURE COMFORT PEN NEEDLES 30G X | |
| SEROSTIM SUBCUTANEOUS | | 8 MM | 180, 185, 186 |
| SOLUTION RECONSTITUTED 4 MG, | | SURE COMFORT PEN NEEDLES 31G X | |
| 5 MG, 6 MG..... | 332 | 5 MM | 180, 185, 186 |
| SIGNIFOR | 265 | SURE COMFORT PEN NEEDLES 31G X | |
| sildenafil citrate oral tablet 20 mg .. | 321, 322 | 6 MM | 180, 185, 186 |
| SIRTURO | 45 | SURE COMFORT PEN NEEDLES 31G X | |
| SKYRIZI..... | 305, 306 | 8 MM | 180, 185, 186 |
| SKYRIZI PEN | 305, 306 | SURE COMFORT PEN NEEDLES 32G X | |
| SM ALCOHOL PREP PAD ... | 180, 185, 186 | 4 MM (OTC)..... | 180, 185, 186 |
| SM ALCOHOL PREP PAD 6-70 % | | SURE COMFORT PEN NEEDLES 32G X | |
| EXTERNAL | 180, 185, 186 | 4 MM (RX)..... | 180, 185, 186 |
| SM ALCOHOL PREP PAD 70 % . | 180, 185, | SURE COMFORT PEN NEEDLES 32G X | |
| 186 | | 6 MM | 180, 185, 186 |
| SM GAUZE PAD 2 | 180, 185, 186 | SURGICAL GAUZE SPONGE PAD 2 | 180, |
| sodium oxybate | 325, 326 | 185, 186 | |
| sofosbuvir-velpatasvir..... | 327 | SYMPAZAN..... | 72 |
| SOMATULINE DEPOT | | SYNRIBO..... | 257 |
| SUBCUTANEOUS SOLUTION 60 | | T | |
| MG/0.2ML, 90 MG/0.3ML | 197 | TABRECTA | 65 |
| SOMAVERT..... | 270 | tadalafil oral tablet 2.5 mg, 5 mg | 341 |
| sorafenib tosylate | 334 | TAFINLAR ORAL CAPSULE | 78 |
| SPRAVATO (56 MG DOSE)..... | 125 | TAFINLAR ORAL TABLET SOLUBLE | 79 |
| SPRAVATO (84 MG DOSE)..... | 125 | TAGRISSE | 261 |
| STERILE GAUZE PAD 2 | 180, 185, 186 | TALVEY..... | 345 |
| STIVARGA | 288 | TALZENNA | 343 |
| STRENSIQ | 35, 36 | TASIGNA ORAL CAPSULE 150 MG, 200 | |
| SUBVENITE ORAL SUSPENSION | 196 | MG, 50 MG..... | 242 |
| sunitinib malate..... | 339 | TAVNEOS | 38 |
| SURE COMFORT ALCOHOL PREP PAD | | TAZVERIK..... | 347 |
| 70 % | 180, 185, 186 | TECHLITE INSULIN SYRINGE 29G X | |
| SURE COMFORT INSULIN SYRINGE | | 1/2 | 180, 185, 186 |
| 28G X 1/2..... | 180, 185, 186 | TECVAYLI..... | 349 |
| SURE COMFORT INSULIN SYRINGE | | TEPMETKO | 352 |
| 29G X 1/2..... | 180, 185, 186 | teriparatide subcutaneous solution pen- | |
| SURE COMFORT INSULIN SYRINGE | | injector 560 mcg/2.24ml | 353 |
| 30G X 1/2..... | 180, 185, 186 | testosterone cypionate intramuscular | |
| SURE COMFORT INSULIN SYRINGE | | solution 100 mg/ml, 200 mg/ml, 200 | |
| 30G X 5/16..... | 180, 185, 186 | mg/ml (1 ml) | 355 |
| SURE COMFORT INSULIN SYRINGE | | testosterone enanthate intramuscular | |
| 31G X 1/4..... | 180, 185, 186 | solution..... | 356 |
| SURE COMFORT INSULIN SYRINGE | | testosterone gel 1.62 % transdermal | 354 |
| 31G X 5/16..... | 180, 185, 186 | testosterone transdermal gel 12.5 mg/act | |
| SURE COMFORT PEN NEEDLES 29G X | | (1%), 20.25 mg/act (1.62%), 25 | |
| 12.7MM | 180, 185, 186 | mg/2.5gm (1%), 50 mg/5gm (1%)..... | 354 |
| | | tetrabenazine | 357 |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | | | |
|--|---------------|--------------------------------|---------------|
| TEVIMBRA..... | 359 | TRUE COMFORT INSULIN SYRINGE | |
| THALOMID ORAL CAPSULE 100 MG, | | 30G X 1/2..... | 181, 185, 186 |
| 150 MG, 200 MG, 50 MG | 358 | TRUE COMFORT INSULIN SYRINGE | |
| THERAGAUZE PAD 2..... | 180, 185, 186 | 30G X 5/16..... | 181, 185, 186 |
| TIBSOVO | 194 | TRUE COMFORT INSULIN SYRINGE | |
| TIGLUTIK..... | 299 | 31G X 5/16..... | 181, 185, 186 |
| TIVDAK | 360 | TRUE COMFORT INSULIN SYRINGE | |
| TODAYS HEALTH PEN NEEDLES 29G | | 32G X 5/16..... | 181, 185, 186 |
| X 12MM..... | 180, 185, 186 | TRUE COMFORT PEN NEEDLES 31G X | |
| TODAYS HEALTH SHORT PEN | | 5 MM | 181, 185, 186 |
| NEEDLE 31G X 8 MM | 180, 185, 186 | TRUE COMFORT PEN NEEDLES 31G X | |
| tolvaptan oral tablet therapy pack | 368 | 6 MM | 181, 185, 186 |
| TOPCARE CLICKFINE PEN NEEDLES | | TRUE COMFORT PEN NEEDLES 32G X | |
| 31G X 6 MM..... | 181, 185, 186 | 4 MM | 181, 185, 186 |
| TOPCARE CLICKFINE PEN NEEDLES | | TRUE COMFORT PRO ALCOHOL PREP | |
| 31G X 8 MM..... | 181, 185, 186 | PAD 70 % | 181, 185, 186 |
| TOPCARE ULTRA COMFORT INS SYR | | TRUE COMFORT PRO INSULIN SYR | |
| 29G X 1/2..... | 181, 185, 186 | 30G X 1/2..... | 181, 185, 186 |
| TOPCARE ULTRA COMFORT INS SYR | | TRUE COMFORT PRO INSULIN SYR | |
| 30G X 5/16..... | 181, 185, 186 | 30G X 5/16..... | 181, 185, 186 |
| TOPCARE ULTRA COMFORT INS SYR | | TRUE COMFORT PRO INSULIN SYR | |
| 31G X 5/16..... | 181, 185, 186 | 31G X 5/16..... | 181, 185, 186 |
| torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 | | TRUE COMFORT PRO INSULIN SYR | |
| mg | 128 | 32G X 5/16..... | 181, 185, 186 |
| tramadol hcl oral solution | 372 | TRUE COMFORT PRO PEN NEEDLES | |
| TRELSTAR MIXJECT | 382 | 31G X 5 MM..... | 181, 185, 186 |
| TREMFYA INTRAVENOUS | 155, 156 | TRUE COMFORT PRO PEN NEEDLES | |
| TREMFYA ONE-PRESS | | 31G X 6 MM..... | 181, 185, 186 |
| SUBCUTANEOUS SOLUTION PEN- | | TRUE COMFORT PRO PEN NEEDLES | |
| INJECTOR..... | 155, 156 | 31G X 8 MM..... | 181, 185, 186 |
| TREMFYA PEN SUBCUTANEOUS | | TRUE COMFORT PRO PEN NEEDLES | |
| SOLUTION AUTO-INJECTOR 200 | | 32G X 4 MM..... | 181, 185, 186 |
| MG/2ML | 155, 156 | TRUE COMFORT PRO PEN NEEDLES | |
| TREMFYA SUBCUTANEOUS | | 32G X 5 MM..... | 181, 185, 186 |
| SOLUTION PREFILLED SYRINGE | 155, | TRUE COMFORT PRO PEN NEEDLES | |
| 156 | | 32G X 6 MM..... | 181, 185, 186 |
| TREMFYA-CD/UC INDUCTION. | 155, 156 | TRUE COMFORT PRO PEN NEEDLES | |
| tretinoin external cream | 369 | 33G X 4 MM..... | 181, 185, 186 |
| tretinoin external gel 0.01 %, 0.025 %.... | 369 | TRUE COMFORT PRO PEN NEEDLES | |
| trientine hcl oral capsule 250 mg..... | 380 | 33G X 5 MM..... | 181, 185, 186 |
| TRIKAFTA ORAL TABLET THERAPY | | TRUE COMFORT PRO PEN NEEDLES | |
| PACK..... | 108 | 33G X 6 MM..... | 181, 185, 186 |
| TRIKAFTA ORAL THERAPY PACK.. | 108 | TRUEPLUS 5-BEVEL PEN NEEDLES | |
| TRUE COMFORT ALCOHOL PREP | | 29G X 12.7MM..... | 181, 185, 186 |
| PADS PAD 70 % | 181, 185, 186 | TRUEPLUS 5-BEVEL PEN NEEDLES | |
| | | 31G X 5 MM..... | 181, 185, 186 |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | | | |
|--|--------------------|---|------------------|
| TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM..... | 181, 185, 186 | ULTICARE INSULIN SYRINGE 30G X 5/16 | 182, 185, 186 |
| TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM..... | 181, 185, 186 | ULTICARE INSULIN SYRINGE 31G X 1/4 | 182, 185, 186 |
| TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM..... | 182, 185, 186 | ULTICARE INSULIN SYRINGE 31G X 5/16 | 182, 185, 186 |
| TRUEPLUS INSULIN SYRINGE 28G X 1/2 | 182, 185, 186 | ULTICARE MICRO PEN NEEDLES 32G X 4 MM..... | 182, 185, 186 |
| TRUEPLUS INSULIN SYRINGE 29G X 1/2 | 182, 185, 186 | ULTICARE MINI PEN NEEDLES 30G X 5 MM | 182, 185, 186 |
| TRUEPLUS INSULIN SYRINGE 30G X 5/16 | 182, 185, 186 | ULTICARE MINI PEN NEEDLES 31G X 6 MM | 182, 185, 186 |
| TRUEPLUS INSULIN SYRINGE 31G X 5/16 | 182, 185, 186 | ULTICARE MINI PEN NEEDLES 32G X 6 MM | 182, 185, 186 |
| TRUEPLUS PEN NEEDLES 29G X 12MM | 182, 185, 186 | ULTICARE PEN NEEDLES 29G X 12.7MM (OTC)..... | 182, 185, 186 |
| TRUEPLUS PEN NEEDLES 31G X 5 MM | 182, 185, 186 | ULTICARE PEN NEEDLES 29G X 12.7MM (RX)..... | 183, 185, 186 |
| TRUEPLUS PEN NEEDLES 31G X 6 MM | 182, 185, 186 | ULTICARE PEN NEEDLES 31G X 5 MM | 183, 185, 186 |
| TRUEPLUS PEN NEEDLES 31G X 8 MM | 182, 185, 186 | ULTICARE SHORT PEN NEEDLES 30G X 8 MM..... | 183, 185, 186 |
| TRUEPLUS PEN NEEDLES 32G X 4 MM | 182, 185, 186 | ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC)..... | 183, 185, 186 |
| TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR | 151 | ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX) | 183, 185, 186 |
| TRUQAP ORAL TABLET 200 MG..... | 64 | ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM..... | 183, 185, 186 |
| TRUQAP ORAL TABLET THERAPY PACK 160 MG | 64 | ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM..... | 183, 185, 186 |
| TRUXIMA..... | 308, 309 | ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM..... | 183, 185, 186 |
| TUKYSA ORAL TABLET 150 MG, 50 MG | 383 | ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM..... | 183, 185, 186 |
| TURALIO | 276 | ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM..... | 183, 185, 186 |
| TYENNE..... | 362, 363, 364, 365 | ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM..... | 183, 185, 186 |
| TYMLOS | 1 | ULTIGUARD SAFEPACK SYR/NEEDLE 30G X 1/2..... | 183, 185, 186 |
| U | | ULTIGUARD SAFEPACK SYR/NEEDLE 31G X 5/16..... | 183, 185, 186 |
| UBRELVY..... | 384 | ULTILET ALCOHOL SWABS PAD ... | 183, 185, 186 |
| UDENYCA ONBODY..... | 268 | ULTILET PEN NEEDLE 29G X 12.7MM | 183, 185, 186 |
| ULTICARE INSULIN SAFETY SYR 29G X 1/2..... | 182, 185, 186 | | |
| ULTICARE INSULIN SYRINGE 28G X 1/2 | 182, 185, 186 | | |
| ULTICARE INSULIN SYRINGE 29G X 1/2 | 182, 185, 186 | | |
| ULTICARE INSULIN SYRINGE 30G X 1/2 | 182, 185, 186 | | |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | |
|--|--|
| ULTILET PEN NEEDLE 31G X 5 MM 183, 185, 186 | ULTRACARE PEN NEEDLES 32G X 5 MM 184, 185, 186 |
| ULTILET PEN NEEDLE 31G X 8 MM 183, 185, 186 | ULTRACARE PEN NEEDLES 32G X 6 MM 184, 185, 186 |
| ULTILET PEN NEEDLE 32G X 4 MM 183, 185, 186 | ULTRACARE PEN NEEDLES 33G X 4 MM 184, 185, 186 |
| ULTRA COMFORT INSULIN SYRINGE 30G X 5/16..... 183, 185, 186 | ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2..... 183, 185, 186 |
| ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM..... 183, 185, 186 | ULTRA-THIN II INS SYR SHORT 30G X 5/16 183, 185, 186 |
| ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM..... 183, 185, 186 | ULTRA-THIN II INS SYR SHORT 31G X 5/16 184, 185, 186 |
| ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM..... 183, 185, 186 | ULTRA-THIN II INSULIN SYRINGE 29G X 1/2..... 184, 185, 186 |
| ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM..... 183, 185, 186 | ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM..... 184, 185, 186 |
| ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2..... 183, 185, 186 | ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM..... 184, 185, 186 |
| ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16..... 183, 185, 186 | ULTRA-THIN II PEN NEEDLES 29G X 12.7MM 184, 185, 186 |
| ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16..... 183, 185, 186 | UNIFINE OTC PEN NEEDLES 31G X 5 MM 184, 185, 186 |
| ULTRA FLO INSULIN SYRINGE 29G X 1/2 183, 185, 186 | UNIFINE OTC PEN NEEDLES 32G X 4 MM 184, 185, 186 |
| ULTRA FLO INSULIN SYRINGE 30G X 1/2 183, 185, 186 | UNIFINE PEN NEEDLES 32G X 4 MM 184, 185, 186 |
| ULTRA FLO INSULIN SYRINGE 30G X 5/16 183, 185, 186 | UNIFINE PENTIPS 29G X 12MM 184, 185, 186 |
| ULTRA FLO INSULIN SYRINGE 31G X 5/16 183, 185, 186 | UNIFINE PENTIPS 31G X 6 MM 184, 185, 186 |
| ULTRA THIN PEN NEEDLES 32G X 4 MM 183, 185, 186 | UNIFINE PENTIPS 31G X 8 MM 184, 185, 186 |
| ULTRACARE INSULIN SYRINGE 30G X 1/2 184, 185, 186 | UNIFINE PENTIPS 32G X 4 MM 184, 185, 186 |
| ULTRACARE INSULIN SYRINGE 30G X 5/16 184, 185, 186 | UNIFINE PENTIPS PLUS 29G X 12MM 184, 185, 186 |
| ULTRACARE INSULIN SYRINGE 31G X 5/16 184, 185, 186 | UNIFINE PENTIPS PLUS 31G X 6 MM 184, 185, 186 |
| ULTRACARE PEN NEEDLES 31G X 5 MM 184, 185, 186 | UNIFINE PENTIPS PLUS 32G X 4 MM 184, 185, 186 |
| ULTRACARE PEN NEEDLES 31G X 6 MM 184, 185, 186 | UNIFINE PROTECT PEN NEEDLE 30G X 5 MM 184, 185, 186 |
| ULTRACARE PEN NEEDLES 31G X 8 MM 184, 185, 186 | UNIFINE PROTECT PEN NEEDLE 30G X 8 MM 184, 185, 186 |
| ULTRACARE PEN NEEDLES 32G X 4 MM 184, 185, 186 | UNIFINE PROTECT PEN NEEDLE 32G X 4 MM 184, 185, 186 |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

| | | | |
|---|---------------|---|-------------|
| UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM..... | 184, 185, 186 | VERIFINE INSULIN PEN NEEDLE 32G X 6 MM..... | 185, 186 |
| UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM..... | 184, 185, 186 | VERIFINE INSULIN SYRINGE 28G X 1/2 | 185, 186 |
| UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM..... | 184, 185, 186 | VERIFINE INSULIN SYRINGE 29G X 1/2 | 185, 186 |
| UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM..... | 184, 185, 186 | VERIFINE INSULIN SYRINGE 30G X 1/2 | 185, 186 |
| UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM..... | 184, 185, 186 | VERIFINE INSULIN SYRINGE 30G X 5/16 | 185, 186 |
| UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM..... | 184, 185, 186 | VERIFINE INSULIN SYRINGE 31G X 5/16 | 185, 186 |
| UNIFINE ULTRA PEN NEEDLE 31G X 5 MM | 184, 185, 186 | VERIFINE PLUS PEN NEEDLE 31G X 5 MM | 185, 186 |
| UNIFINE ULTRA PEN NEEDLE 31G X 6 MM | 184, 185, 186 | VERIFINE PLUS PEN NEEDLE 31G X 8 MM | 185, 186 |
| UNIFINE ULTRA PEN NEEDLE 31G X 8 MM | 184, 185, 186 | VERIFINE PLUS PEN NEEDLE 32G X 4 MM | 185, 186 |
| UNIFINE ULTRA PEN NEEDLE 32G X 4 MM | 184, 185, 186 | VERQUVO | 402 |
| UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG | 316 | VERZENIO..... | 6 |
| UPTRAVI TITRATION..... | 316 | VITRAKVI ORAL CAPSULE 100 MG, 25 MG | 199 |
| ustekinumab-aauz | 387, 388 | VITRAKVI ORAL SOLUTION | 199 |
| V | | VIVIMUSTA | 49 |
| VALCHLOR..... | 225 | VIZIMPRO | 80 |
| VALUE HEALTH INSULIN SYRINGE 29G X 1/2..... | 184, 185, 186 | VONJO | 263 |
| VANFLYTA | 287 | VOQUEZNA | 405 |
| VANISHPOINT INSULIN SYRINGE 29G X 5/16..... | 185, 186 | VORANIGO | 406 |
| VANISHPOINT INSULIN SYRINGE 30G X 3/16..... | 185, 186 | voriconazole oral suspension reconstituted | 407 |
| VANISHPOINT INSULIN SYRINGE 30G X 5/16..... | 185, 186 | VOSEVI..... | 328, 329 |
| VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG..... | 401 | VOWST | 130 |
| VENCLEXTA STARTING PACK | 401 | VP INSULIN SYRINGE 29G X 1/2 | 185, 186 |
| VEOZAH | 134, 135 | VUMERITY | 94 |
| VERIFINE INSULIN PEN NEEDLE 29G X 12MM..... | 185, 186 | VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML..... | 139 |
| VERIFINE INSULIN PEN NEEDLE 31G X 5 MM..... | 185, 186 | VYLOY..... | 412 |
| | | VYNDAMAX..... | 342 |
| | | W | |
| | | WEBCOL ALCOHOL PREP LARGE PAD 70 % | 185, 186 |
| | | WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM..... | 185, 186 |
| | | WELIREG..... | 48 |
| | | WINREVAIR..... | 335, 336 |

Valor Health Plan 2026 Formulary Prior Authorization Criteria

X

XALKORI ORAL CAPSULE..... 76
XALKORI ORAL CAPSULE SPRINKLE
150 MG, 20 MG, 50 MG 77
XDEMVY..... 218
XELJANZ..... 366, 367
XELJANZ XR 366, 367
XERMELO 351
XIFAXAN ORAL TABLET 200 MG, 550
MG 296
XOLAIR 258, 259, 260
XOSPATA 146
XPOVIO (100 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 50
MG 317
XPOVIO (40 MG ONCE WEEKLY) ORAL
TABLET THERAPY PACK 10 MG, 40
MG 317
XPOVIO (40 MG TWICE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG 317
XPOVIO (60 MG ONCE WEEKLY) ORAL
TABLET THERAPY PACK 60 MG.. 317
XPOVIO (60 MG TWICE WEEKLY)... 317
XPOVIO (80 MG ONCE WEEKLY) ORAL
TABLET THERAPY PACK 40 MG, 80
MG 317
XPOVIO (80 MG TWICE WEEKLY)... 317

XTANDI ORAL CAPSULE..... 118
XTANDI ORAL TABLET 40 MG, 80 MG
..... 118

Y

YERVOY 191
YESINTEK..... 393, 394, 395, 396
YONSA..... 8
YUFLYMA (1 PEN)..... 14, 15
YUFLYMA (2 SYRINGE)..... 14, 15
YUFLYMA-CD/UC/HS STARTER .. 14, 15
YUTREPIA..... 379

Z

ZEJULA ORAL CAPSULE 246
ZEJULA ORAL TABLET..... 246
ZELBORAF..... 400
ZEVRX STERILE ALCOHOL PREP PAD
PAD 70 % 185, 186
ZIIHERA..... 408
ZIRABEV 53
ZOLADEX..... 154
ZTALMY 143
ZURZUVAE ORAL CAPSULE 20 MG, 25
MG, 30 MG..... 414
ZYDELIG 159
ZYKADIA ORAL TABLET 67
ZYNLONTA..... 216
ZYNYZ..... 292